CRC for Mental Health


Ayton, S., Diouf, I., Bush, A.I., Alzheimer’s Disease Neuroimaging Initiative (2018). Evidence that iron accelerates Alzheimer’s pathology, a CSF biomarker study. Journal of Neurology, Neurosurgery and Psychiatry 89, 456-460.

Baker, J.E., Lim, Y.Y., Jager, J., Ames, A., Lautenschlager, N.T., Robertson, J., … Maruff, P. (2018). Episodic memory and learning dysfunction over an 18-month period in preclinical and prodromal Alzheimer’s disease. Journal of Alzheimer’s disease, 65(3), 977-988.

Beauchamp, L.C., Chan, J., Hung, L., Padman, B., Vella, L., Liu, X., … Barnham, K. (2018). Ablation of tau causes an olfactory deficit in a murine model of Parkinson’s disease. Acta Neuropathologica Communications, 6(1), 57.

Belaidi, A.A., Gunn, A.P., Wong, B.X., Ayton, S., Appukuttan, A.T., Roberts, B.R., … Bush, A.I. (2018). Marked age-related changes in brain iron homeostasis in Amyloid Protein Precursor knockout mice. Neurotherapeutics, Epub.

Chatterjee, P., Goozee, K., Sohrabi, H.R., Shen, K., Shah, T., Asih, P.R.,… Martins, R.N. (2018) Association of plasma neurofilament light chain with neocortical amyloid-β load and cognitively performance in cognitively normal elderly participants. Journal of Alzheimer’s disease, 63, 479-487.

Chau, E., Mostaid, M., Cropley, V., McGorry, P., Pantelis, C., Bousman, C., Everall, I.P. (2018) Downregulation of plasma SELENBP1 protein in patients with recent-onset schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry, 85, 1-6.

Cropley, V., Ganella, E., Wannan, C., Zalesky, A., Van Rheenen, T.V., Bousman, C., … Pantelis, C. (2018). Frontostriatal connectivity in treatment-resistant schizophrenia: relationship to positive symptoms and cognitive flexibility. Schizophrenia Bulletin, 44 (Suppl 1), S176-177.

Dang, C., Harrington, K.D., Lim, Y.Y., Ames, D., Hassenstab, J., Laws, S.M.,…AIBL Research Group (2018). Relationship between amyloid-β positivity and progression to mild cognitive impairment or dementia over 8 years in cognitively normal older adults. Journal of Alzheimer’s Disease, 65(4), 1313-1325.

Dean, B. (2018). Irreproducible data, Problems and solutions for psychiatry. Australian and New Zealand Journal of Psychiatry 52, 10-12.

Dean, B., Gibbons, A., Gogos, A., Udawela, M., Thomas, E., Scarr, E. (2018). Studies on prostaglandin-endoperoxide synthase 1, Lower levels in schizophrenia and after treatment with antipsychotic drugs in conjunction with aspirin. International Journal of Neuropsychopharmacology, 21,216-225.

Doecke, J.D., Rembach, A., Villemagne, V.L., Varghese, S., Rainey-Smith, S., Sarros, S.,… AIBL Research Group (2018). Concordance between cerebrospinal fluid biomarkers with Alzheimer’s disease pathology between three independent assay platforms. Journal of Alzheimer’s Disease, 61, 169-183.

Ganella, E.P., Seguin, C., Pantelis, C., Whittle, S., Baune, B.T., Olver, J., … Bartholomeusz, C.F. (2018). Resting-state functional brain networks in first-episode psychosis, A 12 month follow-up study. Australian & New Zeland Journal of Psychiatry, 52, 864-875.

Gibbons, A., Udawela, M., Dean, B. (2018). Non-coding RNA as novel players in the pathophysiology of schizophrenia. Non-coding RNA 4(2), 11.

Glahn, D.C., Nimgaonkar, V.L., Raventós, H., Contreras, J., McIntosh, A.M., Jablensky, A., … Blangero, J. (2018). Rediscovering the Value of Families for Psychiatric Genetics Research. Molecular Psychiatry, Epub.

Han, L.K.M., Aghajani, M., Clark, S.L., Chan, R.F., Hattab, M.W., Shabalin, A.A., …Penninx, B.W.J.H. (2018). Epigenetic aging in major depressive disorder. American Journal of Psychiatry 175, 744-782.

Harrington, K. (2018). Harness the power of groups to beat the ‘PhD blues’. Nature, 559, 143-144.

Harrington, K.D., Dang, C., Lim, Y.Y., Ames, D., Laws, S.M., Pietrzak, R.H., Rainey-Smith, S., Robertson, J., Rowe, C.C., Salvado, O., Villemagne, V.L., Masters, C.L., Maruff, P., for the AIBL Research Group (2018). The effect of preclinical Alzheimer’s disease on age-related changes in intelligence in cognitively normal older adults. Intelligence 70, 22-29.

Harrington KD, Schembri A, Lim, Y.Y., Dang, C., Ames, D., Hassenstab, J., … AIBL Research Group (2018). Estimates of age-related memory decline are inflated by unrecognised Alzheimer’s disease. Neurobiology of Aging 70, 170-179.

Khan, F.F., Melton, P.E., McCarthy, N.S., Morar, B., Blangero, J., Moses, E.K., Jablensky, A. (2018). Whole genome sequencing of 91 multiplex schizophrenia families reveals increased burden of rare, exonic copy number variation in schizophrenia probands and genetic heterogeneity. Schizophrenia Research, 197,337 – 345.

Kidnapillai, S., Bortolasci, C.C., Udawela, M., Panizzutti, B., Spolding, B., Connor, T., … Walder, K. (2018). The use of a Gene Expression Signature and Connectivity Map to repurpose drugs for Bipolar Disorder. World Journal Biological Psychiatry, 29, 1-28.

Kottaram, A., Johnston, L., Ganella, E., Pantelis, C., Ramamohanarao, K., Zalesky, A. (2018). Spatio-temporal dynamics of resting-state brain networks improve single-subject prediction of schizophrenia diagnosis. Human Brain Mapping,

Lim, Y.Y., Kalinowski, P., Pietrzak, R.H., Laws, S.M., Burnham, S.C., Ames, D., …Maruff, P.T. (2018). Association of β-Amyloid and Apolipoprotein Eε4 with memory decline in preclinical Alzheimer’s disease JAMA Neurology, 75, 488-494.

Martins, R.N., Villemagne, V., Sohrabi, H.R., Chatterjee, P., Shah, T.M., Verdile, G., … Masters, C.L. (2018). Alzheimer’s disease, a journey from amyloid peptides and oxidative stress, to biomarker technologies and disease prevention strategies – gains from AIBL and DIAN cohort studies. Journal of Alzheimer’s Disease 62, 965-992.

McCarthy, N.S., Badcock, J.C., Clark, M.L., Knowles, E.E.M., Cadby, G., Melton, P.E., …Jablensky, A. (2018). Assessment of cognition and personality as potential endophenotypes in the Western Australian Family Study of Schizophrenia. Schizophrenia Bulletin, 44,908-921.

Morris, G., Berk, M., Carvalho, A.F., Maes, M., Walker, A.J., Puri, B.K. (2018). Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neuroprogressive diseases. Behavioural Brain Research 341,154-175.

Morris, G., Berk, M., Maes, M., Puri, B.K. Could Alzheimer’s Disease originate in the periphery and if so how so? (2018). Molecular Neurobiology.

Parkin, G.M., Udawela, M., Gibbons, A., Dean, B. (2018). Glutamate transporters, EAAT1 and EAAT2, are potentially important in the pathophysiology and treatment of schizophrenia and affective disordersWorld Journal of Psychiatry, 8, 57- 63.

Pereira, C., Chavarria, V., Vian, J., Ashton, M.M., Berk, M., Marx, W., Dean, O.M. Mitochondrial Agents for Bipolar Disorder. (2018). International Journal of Neuropsychopharmacology. 21, 550-569.

Porter, T., Burnham, S.C., Doré, V., Savage, G., Bourgeat, P., Begemann, K., …Laws, S.M. (2018). KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden. Scientific Reports, 8, 2034.

Porter, T., Villemagne, V.L., Savage, G., Milicic, .L, Lim, Y.Y., Maruff, P., … for the AIBL Research Group (2018) Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimer’s disease. Personalized Medicine in Psychiatry 7/8, 14-20.

Scarr, E., Hopper, S., Vos, V., Seo, M.S., Everall, I.P., Aumann, T.D., …Dean, B. (2018). Low levels of muscarinic M1 receptor positive neurons in cortical layers III and V in Brodmann’s areas 9 and 17 from individuals with schizophrenia. Journal of Psychiatry and Neuroscience, 43, 170202.

Scarr, E., Udawela, M., Dean, B. (2018). Changed frontal pole gene expression suggest altered interplay between neurotransmitter, developmental and inflammatory pathways in schizophrenia. NPJ Schizophrenia, 4, 4.

Scarr, E., Udawela, M., Thomas, E.A., Dean, B. (2018). Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor. Molecular Psychiatry, 23, 295-303.

Skvarc, D.R., Berk, M., Byrne, L.K., Dean, O.M., Dodd, S., Lewis, M., …Gray L (2018). Post-Operative Cognitive Dysfunction: An exploration of the inflammatory hypothesis and novel therapies. Neuroscience and Biobehavioral Reviews, 84, 116–133.

Wannan, C.M.J., Bartholomeusz, C.F., Cropley, V.L., Van Rheenen, T.E., Panayiotou, A., Brewer, W.J., Proffitt, T.M., Henry, L., Harris, M.G., Velakoulis, D., McGorry, P., Pantelis, C., Wood, S.J. (2018) Deterioration of visuospatial associative memory following a first psychotic episode, a long-term follow-up study. Psychol Med, 48, 132-141.

Zheng, W., Zhang, Q.E., Cai, D.B., Yang, X.H., Qiu, Y., Ungvari, G.S., Ng, C.H., Berk, M., Ning ,Y.P., Xiang, Y.T. (2018). N-acetylcysteine for major mental disorders, a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand, 137, 391-400.


Almeida, O. P., Morar, B., Hankey, G. J., Yeap, B. B., Golledge, J., Jablensky, A., & Flicker, L. (2017). Longevity Klotho gene polymorphism and the risk of dementia in older men. Maturitas, 101, 1-5.

Ayton, S., Faux, N. G., & Bush, A. I. (2017). Association of cerebrospinal fluid ferritin level with preclinical cognitive decline in APOE-ε4 carriers. JAMA Neurology, 74(1), 122.

Ayton, S., Fazlollahi, A., Bourgeat, P., Raniga, P., Ng, A., Lim, Y.Y.,… Bush, A.I. (2017). Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline. Brain 140, 2112–2119.

Badcock, J. C., Dehon, H., & Larøi, F. (2017). Hallucinations in healthy older adults: An overview of the literature and perspectives for future research. Frontiers in Psychology, 8.

Baker, J. E., Lim, Y. Y., Pietrzak, R. H., Hassenstab, J., Snyder, P. J., Masters, C. L., & Maruff, P. (2017). Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 6, 108-121.

Berk, M., & Berk, L. (2017). Cognition in psychiatric disorders: from models to management. The Lancet Psychiatry, 4(3), 173-175.

Betrie, A. H., Ayton, S., Bush, A. I., Angus, J. A., Lei, P., & Wright, C. E. (2017). Evidence of a cardiovascular function for microtubule-associated protein tau. Journal of Alzheimer’s Disease, 56(2), 849-860.

Bousman, C. A., Müller, D. J., Ng, C. H., Byron, K., Berk, M., & Singh, A. B. (2017). Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder. Pharmacogenetics and Genomics, 27(1), 1-6.

Bousman, C. A., Forbes, M., Jayaram, M., Eyre, H., Reynolds, C. F., Berk, M., . . . Ng, C. (2017). Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic tools. BMC Psychiatry, 17(1).

Campos-Carli, S. M., Araújo, M. S., Silveira, A. C., Rezende, V. B., Rocha, N. P., Ferretjans, R., . . . Teixeira, A. L. (2017). Cannabinoid receptors on peripheral leukocytes from patients with schizophrenia: Evidence for defective immunomodulatory mechanisms. Journal of Psychiatric Research, 87, 44-52.

Cardoso, B. R., Hare, D. J., Bush, A. I., Li, Q., Fowler, C. J., Masters, C. L., . . . Roberts, B. R. (2017). Selenium levels in serum, red blood cells, and cerebrospinal fluid of Alzheimer’s disease patients: A report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). Journal of Alzheimer’s Disease, 57(1), 183-193.

Cardoso, B. R., Hare, D. J., Lind, M., Mclean, C. A., Volitakis, I., Laws, S. M., . . . Roberts, B. R. (2017). The APOE ε4 allele is associated with lower selenium levels in the brain: Implications for Alzheimer’s disease. ACS Chemical Neuroscience, 8(7), 1459-1464.

Data-Franco, J., Singh, A., Popovic, D., Ashton, M., Berk, M., Vieta, E., . . . Dean, O. M. (2017). Beyond the therapeutic shackles of the monoamines: New mechanisms in bipolar disorder biology. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 72, 73-86.

Dean, O. M., Kanchanatawan, B., Ashton, M., Mohebbi, M., Ng, C. H., Maes, M., . . . Berk, M. (2017). Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. Australian & New Zealand Journal of Psychiatry, 51(8), 829-840.

Di Biase, M. A., Cropley, V. L., Baune, B. T., Olver, J., Amminger, G. P., Phassouliotis, C., . . . Zalesky, A. (2017). White matter connectivity disruptions in early and chronic schizophrenia. Psychological Medicine, 1-14.

Duché, Q., Saint-Jalmes, H., Acosta, O., Raniga, P., Bourgeat, P., Doré, V., . . . Salvado, O. (2017). Partial volume model for brain MRI scan using MP2RAGE. Human Brain Mapping.

Fernandes, B. S., Williams, L. M., Steiner, J., Leboyer, M., Carvalho, A. F., & Berk, M. (2017). The new field of ‘precision psychiatry’. BMC Medicine, 15(1).

Ferreira, D., Falahati, F., Linden, C., Buckley, R. F., Ellis, K. A., Savage, G., . . . Westman, E. (2017). A ‘Disease Severity Index’ to identify individuals with subjective memory decline who will progress to mild cognitive impairment or dementia. Scientific Reports, 7, 44368.

Flicker, L., Morar, B., Hankey, G., Yeap, B., Golledge, J., Jablensky, A., & Almeida, O. (2017). Longevity Klotho gene polymorphism and the risk of dementia in older men. Innovation in Aging, 1(Suppl_1), 906-906.

Frost, S., Bhuiyan, A., Offerman, D., Doecke, J., Macaulay, S., Sohrabi, H., . . . Kanagasingam, Y. (2017). Modulation of retinal arteriolar central reflection by APOE genotype. Current Alzheimer Research, 14(999), 1-1.

Ganella, E.P., Bartholomeusz, C.F., Seguin, C., Whittle, S., Bousman, C., Phassouliotis, C., … Zalesky, A. (2017). Functional brain networks in treatment-resistant schizophrenia. Schizophrenia Research, 184, 73-81.

Ganella, E. P., Seguin, C., Bartholomeusz, C. F., Whittle, S., Bousman, C., Wannan, C. M., . . . Zalesky, A. (2017). Risk and resilience brain networks in treatment-resistant schizophrenia. Schizophrenia Research.

Gardener, S. L., Rainey-Smith, S. R., Sohrabi, H. R., Weinborn, M., Verdile, G., Fernando, W. B., . . . Martins, R. N. (2017). Increased carbohydrate intake is associated with poorer performance in verbal memory and attention in an APOE genotype-dependent manner. Journal of Alzheimer’s Disease, 58(1), 193-201.

Golzan, S., Goozee, K., Georgevsky, D., Avolio, A., Chatterjee, P., Shen, K., . . . Graham, S. L. (2017). Retinal vascular and structural changes are associated with amyloid burden in the elderly: Ophthalmic biomarkers of preclinical Alzheimer’s disease. Alzheimer’s Research & Therapy, 9(1).

Goozee, K., Chatterjee, P., James, I., Shen, K., Sohrabi, H. R., Asih, P. R., . . . Martins, R. N. (2017). Elevated plasma ferritin in elderly individuals with high neocortical amyloid-β load. Molecular Psychiatry.

Goozee, K., Chatterjee, P., James, I., Shen, K., Sohrabi, H. R., Asih, P. R., . . . Martins, R. N. (2017). Alterations in erythrocyte fatty acid composition in preclinical Alzheimer’s disease. Scientific Reports, 7(1).

Gupta, V. B., Hone, E., Pedrini, S., Doecke, J., Obryant, S., James, I., . . . Martins, R. N. (2017). Altered levels of blood proteins in Alzheimer’s disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 8, 60-72.

Hamazaki, K., Maekawa, M., Toyota, T., Dean, B., Hamazaki, T., & Yoshikawa, T. (2017). Fatty acid composition of the postmortem corpus callosum of patients with schizophrenia, bipolar disorder, or major depressive disorder. European Psychiatry, 39, 51-56.

Harrington, K. D., Lim, Y. Y., Ames, D., Hassenstab, J., Laws, S. M., Martins, R. N., . . . Maruff, P. (2017). Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 8, 156-164.

Hollands, S., Lim, Y. Y., Laws, S. M., Villemagne, V. L., Pietrzak, R. H., Harrington, K., . . . Maruff, P. (2017). APOE ɛ4 genotype, amyloid, and clinical disease progression in cognitively normal older adults. Journal of Alzheimer’s Disease, 57(2), 411-422.

Laws, S.M., Gaskin, S., Woodfield, A., Srikanth, V., Bruce, D., Fraser, P.E., …Verdile, G. (2017). Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Scientific reports, 6, 9766.

Lim, Y. Y., Williamson, R., Laws, S. M., Villemagne, V. L., Bourgeat, P., Fowler, C., . . . Maruff, P. (2017). Effect of APOE genotype on amyloid deposition, brain volume, and memory in cognitively normal older individuals. Journal of Alzheimer’s Disease, 58(4), 1293-1302.

McCarthy, N. S., Melton, P. E., Ward, S. V., Allan, S. M., Dragovic, M., Clark, M. L., . . . Jablensky, A. (2017). Exome array analysis suggests an increased variant burden in families with schizophrenia. Schizophrenia Research, 185, 9-16.

Morar, B., Badcock, J. C., Phillips, M., Almeida, O. P., & Jablensky, A. (2017). The longevity gene Klotho is differentially associated with cognition in subtypes of schizophrenia. Schizophrenia Research.

Morris, G., Walder, K., Mcgee, S. L., Dean, O. M., Tye, S. J., Maes, M., & Berk, M. (2017). A model of the mitochondrial basis of bipolar disorder. Neuroscience & Biobehavioral Reviews, 74, 1-20.

Mostaid, M. S., Lee, T. T., Chana, G., Sundram, S., Shannon Weickert, C., Pantelis, C., … Bousman, C. (2017). Peripheral transcription of NRG-ErbB pathway genes are upregulated in treatment-resistant schizophrenia. Frontiers in Psychiatry, 8,225.

Mostaid, M. S., Lee, T. T., Chana, G., Sundram, S., Shannon Weickert, C., Pantelis, C., … Bousman, C. (2017). Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients. Translational Psychiatry, 7(12), 1280.

Mostaid, M. S., Mancuso, S. G., Liu, C., Sundram, S., Pantelis, C., Everall, I. P., & Bousman, C. A. (2017). Meta-analysis reveals associations between genetic variation in the 5′ and 3′ regions of Neuregulin-1 and schizophrenia. Translational Psychiatry, 7(1).

Mukherjee, S., Kapp, E. A., Lothian, A., Roberts, A. M., Vasil’Ev, Y. V., Boughton, B. A., . . . Roberts, B. R. (2017). Characterization and identification of dityrosine cross-linked peptides using tandem mass spectrometry. Analytical Chemistry, 89(11), 6136-6145.

Pedrini, S., Gupta, V.B., Hone, E., Doecke, J., O’Bryant, S., James, I., and the AIBL Research Group (2017). A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort. Scientific Reports, 7, 14057

Pietrzak, R. H., Laws, S. M., Lim, Y. Y., Bender, S. J., Porter, T., Doecke, J., . . . Maruff, P. (2017). Plasma cortisol, brain amyloid-β, and cognitive decline in preclinical Alzheimer’s disease: A 6-Year prospective cohort study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2(1), 45-52.

Quek, C., & Hill, A. F. (2017). The role of extracellular vesicles in neurodegenerative diseases. Biochemical and Biophysical Research Communications, 483(4), 1178-1186.

Roberts, B. R., Lind, M., Wagen, A. Z., Rembach, A., Frugier, T., Li, Q., . . . Masters, C. L. (2017). Biochemically-defined pools of amyloid-β in sporadic Alzheimer’s disease: correlation with amyloid PET. Brain, 140(5), 1486-1498.

Saini, S.M., Mancuso, S.G., Mostaid, M.S., Liu, C., Pantelis, C., Everall, I.P., Bousman, C.D. (2017). Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk. Translational Psychiatry 7, 1196.

Scaini, G., Fries, G. R., Valvassori, S. S., Zeni, C. P., Zunta-Soares, G., Berk, M., . . . Quevedo, J. (2017). Perturbations in the apoptotic pathway and mitochondrial network dynamics in peripheral blood mononuclear cells from bipolar disorder patients. Translational Psychiatry, 7(5).

Skvarc, D. R., Dean, O. M., Byrne, L. K., Gray, L., Lane, S., Lewis, M., . . . Marriott, A. (2017). The effect of N-acetylcysteine (NAC) on human cognition – A systematic review. Neuroscience & Biobehavioral Reviews, 78, 44-56.

Stevens, B. J., Hare, D. J., Volitakis, I., Cherny, R. A., & Roberts, B. R. (2017). Direct determination of zinc in plasma by graphite furnace atomic absorption spectrometry using palladium/magnesium and EDTA matrix modification with high temperature pyrolysis. J. Anal. At. Spectrom., 32(4), 843-847.

Udawela, M., Scarr, E., Boer, S., Um, J. Y., Hannan, A. J., Mcomish, C., . . . Dean, B. (2017). Isoform specific differences in phospholipase C beta 1 expression in the prefrontal cortex in schizophrenia and suicide. npj Schizophrenia, 3(1).

Vella, L. J., Scicluna, B. J., Cheng, L., Bawden, E. G., Masters, C. L., Ang, C., . . . Hill, A. F. (2017). A rigorous method to enrich for exosomes from brain tissue. Journal of Extracellular Vesicles, 6(1), 1348885.

Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., . . . Rowe, C. C. (2017). Aβ-amyloid and tau imaging in dementia. Seminars in Nuclear Medicine, 47(1), 75-88.

Wang, Y., Spincemaille, P., Liu, Z., Dimov, A., Deh, K., Li, J., …Prince, M.R. (2017). Clinical quantitative susceptibility mapping (QSM), Biometal imaging and its emerging roles in patient care. Journal of Magnetic Resonance Imaging, 46, 951-971.


Arandjelovic, K., Eyre, H.A., Forbes, M.P., Bauer, R., Aggarwal, S., Singh, A.B., Baune, B.T., Everall, I., Berk, M., & Ng, C. (2016). Mental health system development in Asia: Does Australia have a role?Australian and New Zealand Journal of Psychiatry, 0004867416647798.

Ayton, S., Lei, P., Mclean, C., Bush, A. I., & Finkelstein, D. I. (2016). Transferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinson’s substantia nigra. Signal Transduction and Targeted Therapy, 1, 16015.

Badcock, J. C., Panton, K., Cohen, A., & Badcock, D. R. (2016). Both harmful and (some) helpful behaviours from others are associated with increased expression of schizotypal traits. Psychiatry Research, 239, 308-314.

Berger, G.E., Smesny, S., Schäfer, M.R., Milleit, B., Langbein, K., Hipler, U.C., Milleit, C., Klier, C.M., Schlögelhofer, M., Holub, M. & Holzer, I., (2016). Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis. PloS one, 11(2), e0148429.

Berk, M. (2016). Mental health for all Australians. Australian and New Zealand Journal of Psychiatry, 50(4), 301-302.

Billings, J.L., Hare, D.J., Nurjono, M., Volitakis, I., Cherny, R.A., Bush, A.I., Adlard, P.A. & Finkelstein, D.I. (2016). Effects of Neonatal Iron Feeding and Chronic Clioquinol Administration on the Parkinsonian Human A53T Transgenic Mouse. ACS chemical neuroscience, 7(3), 360-366.

Bird, S. M., Sohrabi, H. R., Sutton, T. A., Weinborn, M., Rainey-Smith, S. R., Brown, B., . . . Martins, R. N. (2016). Cerebral amyloid-β accumulation and deposition following traumatic brain injury – A narrative review and meta-analysis of animal studies. Neuroscience & Biobehavioral Reviews, 64, 215-228.

Bloch, M.H., Panza, K.E., Yaffa, A., Alvarenga, P.G., Jakubovski, E., Mulqueen, J.M., Landeros-Weisenberger, A. & Leckman, J.F. (2016). N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal of Child and Adolescent Psychopharmacology, 26(4), 327-334.

Bora, E., & Berk, M. (2016). Theory of mind in major depressive disorder: A meta-analysis. Journal of Affective Disorders, 191, 49-55.

Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016). Cognitive remission: a novel objective for the treatment of major depression?. BMC Medicine, 14(1), 1.

Boyce, P. M., & Berk, M. (2016). Biological models of mental illness: implications for therapy development. The Medical Journal of Australia, 204(9), 339-340.

Brennan-Olsen, S.L., Page, R.S., Berk, M., Riancho, J.A., Leslie, W.D., Wilson, S.G., Saban, K.L., Janusek, L., Pasco, J.A., Hodge, J.M. & Quirk, S.E. (2016). DNA methylation and the social gradient of osteoporotic fracture: A conceptual model. Bone, 84, 204-212.

Brown, B. M., Rainey-Smith, S. R., Villemagne, V. L., Weinborn, M., Bucks, R. S., Sohrabi, H. R., . . . Martins, R. N. (2016). The relationship between sleep quality and brain amyloid burden. Sleep, 39(5), 1063-1068.

Buckley, R. F., Villemagne, V. L., Masters, C. L., Ellis, K. A., Rowe, C. C., Johnson, K., . . . Amariglio, R. (2016). A conceptualization of the utility of subjective cognitive decline in clinical trials of preclinical Alzheimer’s disease. Journal of Molecular Neuroscience, 60(3), 354-361.

Burnham, S. C., Bourgeat, P., Doré, V., Savage, G., Brown, B., Laws, S., . . . Villemagne, V. L. (2016). Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. The Lancet Neurology, 15(10), 1044-1053.

Burnham, S. C., Rowe, C. C., Baker, D., Bush, A. I., Doecke, J. D., Faux, N. G., . . . Villemagne, V. L. (2016). Predicting Alzheimer disease from a blood-based biomarker profile. Neurology, 87(11), 1093-1101.

Carew, M., Dean, B., Bush, A.I., & Cooke, I. (2016). Context matters: communicating the need for biomarkers for mental illnesses to the general public. Australasian Psychiatry.

Carvalho, A.F., Köhler, C.A., Brunoni, A.R., Miskowiak, K.W., Herrmann, N., Lanctôt, K.L., Hyphantis, T.N., Quevedo, J., Fernandes, B.S. & Berk, M. (2016). Bias in Peripheral Depression Biomarkers. Psychotherapy and Psychosomatics, 85(2), 81-90.

Carvalho, A.F., Köhler, C.A., Fernandes, B.S., Quevedo, J., Miskowiak, K.W., Brunoni, A.R., Machado-Vieira, R., Maes, M., Vieta, E. & Berk, M. (2016). Bias in emerging biomarkers for bipolar disorder. Psychological Medicine, 1-11.

Chanen, A. M., Berk, M., & Thompson, K. (2016). Integrating Early Intervention for Borderline Personality Disorder and Mood Disorders. Harvard Review of Psychiatry.

Chatterjee, P., Lim, W.L., Shui, G., Gupta, V.B., James, I., Fagan, A.M., Xiong, C., Sohrabi, H.R., Taddei, K., Brown, B.M. & Benzinger, T. (2016). Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study. Journal of Alzheimer’s Disease, 50(3), 887-894.

Chételat, G., Ossenkoppele, R., Villemagne, V. L., Perrotin, A., Landeau, B., Mézenge, F., . . . Rabinovici, G. D. (2016). Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease. Brain, 139(9), 2528-2539.

Chiu, Y. F., Justice, A. E., & Melton, P. E. (2016). Longitudinal analytical approaches to genetic data. BMC genetics, 17(2), 25.

Czarny, P., Kwiatkowski, D., Toma, M., Gałecki, P., Orzechowska, A., Bobińska, K., . . . Śliwiński, T. (2016). Single-Nucleotide Polymorphisms of genes involved in repair of oxidative DNA damage and the risk of recurrent depressive disorder. Medical Science Monitor, 22, 4455-4474.

Dawson, S. I., Dash, S. R., & Jacka, F. N. (2016). The Importance of Diet and Gut Health to the Treatment and Prevention of Mental Disorders. International Review of Neurobiology Gut Microbiome and Behavior, 325-346.

Davis, J., Eyre, H., Jacka, F.N., Dodd, S., Dean, O., McEwen, S., Debnath, M., McGrath, J., Maes, M., Amminger, P. & McGorry, P.D. (2016). A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neuroscience & Biobehavioral Reviews, 65, 185-194.

Dash, S. R., O’Neil, A., & Jacka, F. N. (2016). Diet and common mental disorders: The imperative to translate evidence into action. Frontiers in Public Health, 4.

Dean, B., & Scarr, E. (2016). COMT genotype is associated with differential expression of muscarinic M1 receptors in human cortex. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.

Dean, B., Copolov, D., & Scarr, E. (2016). Understanding the pathophysiology of schizophrenia: Contributions from the Melbourne Psychiatric Brain Bank. Schizophrenia Research.

Dean, B., Gibbons, A.S., Boer, S., Uezato, A., Meador-Woodruff, J., Scarr, E. & McCullumsmith, R.E. (2016). Changes in cortical N-methyl-d-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide. Australian and New Zealand Journal of Psychiatry, 50(3), 275-283.

Dean, B., Udawela, M., & Scarr, E. (2016). Validating reference genes using minimally transformed qpcr data: findings in human cortex and outcomes in schizophrenia. BMC psychiatry, 16(1), 1.

Dean, B., Thomas, N., Scarr, E., & Udawela, M. (2016). Evidence for impaired glucose metabolism in the striatum, obtained postmortem, from some subjects with schizophrenia. Translational Psychiatry, 6(11).

Dean, O.M., Gray, K.M., Villagonzalo, K.A., Dodd, S., Mohebbi, M., Vick, T., Tonge, B.J. & Berk, M. (2016). A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian and New Zealand Journal of Psychiatry, 0004867416652735.

Dipnall, J. F., Pasco, J. A., Berk, M., Williams, L. J., Dodd, S., Jacka, F. N., & Meyer, D. (2016). Fusing Data Mining, Machine Learning and Traditional Statistics to Detect Biomarkers Associated with Depression. PLoS one, 11(2), 1-23.

Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., . . . Jack, C. R. (2016). Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimer’s & Dementia, 12(3), 292-323.

Duong, A., Che, Y., Ceylan, D., Pinguelo, A., Andreazza, A. C., Young, L. T., & Berk, M. (2016). Regulators of mitochondrial complex I activity: A review of literature and evaluation in postmortem prefrontal cortex from patients with bipolar disorder. Psychiatry research, 236, 148-157.

Fernandes, B. S., Dean, O. M., Dodd, S., Malhi, G. S., & Berk, M. (2016). N-Acetylcysteine in Depressive Symptoms and Functionality: A Systematic Review and Meta-Analysis. The Journal of Clinical Psychiatry, 77(4), 457-466.

Fernandes, B. S., Hodge, J. M., Pasco, J. A., Berk, M., & Williams, L. J. (2016). Effects of depression and serotonergic antidepressants on bone: mechanisms and implications for the treatment of depression. Drugs & Aging, 33(1), 21-25.

Fernandes, B.S., Dash, S., Jacka, F., Dodd, S., Carvalho, A.F., Köhler, C.A., Steiner, J., da Graça Cantarelli, M., Nardin, P., Gonçalves, C.A. & Berk, M. (2016). Leptin in bipolar disorder: A systematic review and meta-analysis. European Psychiatry, 35, 1-7.

Fernandes, B.S., Steiner, J., Bernstein, H.G., Dodd, S., Pasco, J.A., Dean, O.M., Nardin, P., Goncalves, C.A. & Berk, M. (2016). C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Molecular Psychiatry, 21(4), 554-564.

Gardiner, C., Vizio, D. D., Sahoo, S., Théry, C., Witwer, K. W., Wauben, M., & Hill, A. F. (2016). Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. Journal of Extracellular Vesicles, 5(1), 32945.

Gibbons, A., & Dean, B. (2016). The cholinergic system: An emerging drug target for schizophrenia. Current Pharmaceutical Design, 22(14), 2124-2133.

Gibbons, A. S., Jeon, W. J., Scarr, E., & Dean, B. (2016). Changes in muscarinic M2 receptor levels in the cortex of subjects with bipolar disorder and major depressive disorder and in rats after treatment with mood stabilisers and antidepressants. International Journal of Neuropsychopharmacology, 19(4), pyv118.

Gibbons, A., & Dean, B. (2016). The cholinergic system: an emerging drug target for schizophrenia. Current Pharmaceutical Design, 22(14), 2124-2133.

Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016). Bipolar disorder. The Lancet, 387(10027), 1561-1572.

Gunn, A.P., Wong, B.X., Johanssen, T., Griffith, J.C., Masters, C.L., Bush, A.I., Barnham, K.J., Duce, J.A. & Cherny, R.A.  (2016). Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons. Journal of Biological Chemistry, 291(12), 6134-6145.

Gupta, V.B., Doecke, J.D., Hone, E., Pedrini, S., Laws, S.M., Thambisetty, M., Bush, A.I., Rowe, C.C., Villemagne, V.L., Ames, D., & Masters, C.L. (2016). Plasma apolipoprotein J as a potential biomarker for Alzheimer’s disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 3, 18-26.

Hamazaki, K., Maekawa, M., Toyota, T., Iwayama, Y., Dean, B., Hamazaki, T., & Yoshikawa, T. (2016). Fatty acid composition and fatty acid binding protein expression in the postmortem frontal cortex of patients with schizophrenia: A case–control study. Schizophrenia Research171(1), 225-232.

Hare, D. J., Faux, N. G., Roberts, B. R., Volitakis, I., Martins, R. N., & Bush, A. I. (2016). Lead and manganese levels in serum and erythrocytes in Alzheimer’s disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Metallomics, 8, 628-632.

Hare, D.J., Jones, M.W.M., Wimmer, V.C., Jenkins, N.L., de Jonge, M.D., Bush, A.I, & McColl, G. (2016). High-resolution complementary chemical imaging of bio-elements in Caenorhabditis elegans. Metallomics, 8(2), 156-160.

Hare, D.J., Raven, E.P., Roberts, B.R., Bogeski, M., Portbury, S.D., McLean, C.A., Masters, C.L., Connor, J.R., Bush, A.I., Crouch, P.J. and Doble, P.A. (2016). Laser ablation-inductively coupled plasma-mass spectrometry imaging of white and gray matter iron distribution in Alzheimer’s disease frontal cortex. NeuroImage.

Harrington, K. D., Gould, E., Lim, Y. Y., Ames, D., Pietrzak, R. H., Rembach, A., . . . Maruff, P. (2016). Amyloid burden and incident depressive symptoms in cognitively normal older adults. International Journal of Geriatric Psychiatry, 32(4), 455-463.

Heffernan, A. L., Chidgey, C., Peng, P., Masters, C. L., & Roberts, B. R. (2016). The neurobiology and age-related prevalence of the ε4 allele of Apolipoprotein E in Alzheimer’s disease cohorts. Journal of Molecular Neuroscience, 60(3), 316-324.

Holmes, S. E., Esterlis, I., Mazure, C. M., Lim, Y. Y., Ames, D., Rainey-Smith, S., . . . Pietrzak, R. H. (2016). β-Amyloid, APOE and BDNF genotype, and depressive and anxiety symptoms in cognitively normal older women and men. The American Journal of Geriatric Psychiatry, 24(12), 1191-1195.

Hopper, S., Udawela, M., Scarr, E., & Dean, B. (2016). Allosteric modulation of cholinergic system: Potential approach to treating cognitive deficits of schizophrenia. World J Pharmacol, 5(1), 32-43.

Howitt, J., & Hill, A. F. (2016). Exosomes in the pathology of neurodegenerative diseases. Journal of Biological Chemistry, 291(52), 26589-26597.

Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C. C., Villemagne, V. L., . . . Furukawa, K. (2016). Tau imaging with [18F]THK-5351 in progressive supranuclear palsy. European Journal of Neurology, 24(1), 130-136.

Jablensky, A. (2016). Psychiatric classifications: validity and utility. World Psychiatry, 15(1), 26-31.

Jacka, F. N., & Berk, M. (2016). Gut dysbiosis in mania: A viable therapeutic target?. The Australian and New Zealand Journal of Psychiatry, 50(2), 185-185.

Kim, S.W., Jhon, M., Kim, J.M., Smesny, S., Rice, S., Berk, M., Klier, C.M., McGorry, P.D., Schäfer, M.R. & Amminger, G.P. (2016). Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study. PloS one, 11(3), e0151417.

Krämer-Albers, E., & Hill, A. F. (2016). Extracellular vesicles: interneural shuttles of complex messages. Current Opinion in Neurobiology, 39, 101-107.

Kwiatkowski, D., Czarny, P., Toma, M., Jurkowska, N., Sliwinska, A., Drzewoski, J., Bachurska, A., Szemraj, J., Maes, M., Berk, M. & Su, K.P. (2016). Associations between DNA Damage, DNA Base Excision Repair Gene Variability and Alzheimer’s Disease Risk. Dementia and Geriatric Cognitive Disorders, 41(3-4), 152-171.

Lai, C. Y., Scarr, E., Udawela, M., Everall, I., Chen, W. J., & Dean, B. (2016). Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics. World Journal of Psychiatry, 6(1), 102.

Lai, C.Y., Lee, S.Y., Scarr, E., Yu, Y.H., Lin, Y.T., Liu, C.M., Hwang, T.J., Hsieh, M.H., Liu, C.C., Chien, Y.L. & Udawela, M. (2016). Aberrant expression of microRNAs as biomarker for schizophrenia: from acute state to partial remission, and from peripheral blood to cortical tissue. Translational Psychiatry, 6(1), e717.

Lei, P., Ayton, S., Appukuttan, A.T., Moon, S., Duce, J.A., Volitakis, I., Cherny, R., Wood, S.J., Greenough, M., Berger, G. and Pantelis, C., McGorry, P., Yung, A., Finkelstein, D.I., Bush, A.I. (2016). Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Molecular Psychiatry.

Leyton, C. E., Cassidy, B., Villemagne, V. L., Jones, G., Kwok, J. B., Rowe, C. C., . . . Hodges, J. R. (2016). Divergent network patterns of amyloid-β deposition in logopenic and amnestic Alzheimer’s disease presentations. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 1(1), 24-31.

Lim, Y.Y., Laws, S.M., Villemagne, V.L., Pietrzak, R.H., Porter, T., Ames, D., Fowler, C., Rainey-Smith, S., Snyder, P.J., Martins, R.N. & Salvado, O. (2016). Aβ-related memory decline in APOE ε4 noncarriers Implications for Alzheimer disease. Neurology, 86(17), 1635-1642.

Lim, Y. Y., Snyder, P. J., Pietrzak, R. H., Ukiqi, A., Villemagne, V. L., Ames, D., . . . Maruff, P. (2016). Sensitivity of composite scores to amyloid burden in preclinical Alzheimer’s disease: Introducing the Z-scores of attention, verbal fluency, and episodic memory for nondemented older adults composite score. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2, 19-26.

Lim, Y. Y., Villemagne, V. L., Laws, S. M., Pietrzak, R. H., Ames, D., Fowler, C., . . . Maruff, P. (2016). Performance on the Cogstate brief battery is related to amyloid levels and hippocampal volume in very mild dementia. Journal of Molecular Neuroscience, 60(3), 362-370.

Liu, P., Jing, Y., Collie, N. D., Dean, B., Bilkey, D. K., & Zhang, H. (2016). Altered brain arginine metabolism in schizophrenia. Translational Psychiatry, 6(8), e871.

Lothian, A., & Roberts, B. R. (2016). Standards for quantitative metalloproteomic analysis using size exclusion ICP-MS. Journal of Visualized Experiments, (110).

Magalhães, P. V., Dean, O., Andreazza, A. C., Berk, M., & Kapczinski, F. (2016). Antioxidant treatments for schizophrenia. The Cochrane Database of Systematic Reviews, 2, CD008919.

Manso, Y., Comes, G., López-Ramos, J.C., Belfiore, M., Molinero, A., Giralt, M., Carrasco, J., Adlard, P.A., Bush, A.I., Delgado-García, J.M. & Hidalgo, J. (2016). Overexpression of Metallothionein-1 Modulates the Phenotype of the Tg2576 Mouse Model of Alzheimer’s Disease. Journal of Alzheimer’s Disease, 51(1), 81-95.

Martin-Subero, M., Anderson, G., Kanchanatawan, B., Berk, M., & Maes, M. (2016). Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut–brain pathways. CNS Spectrums, 21(02), 184-198.

McCarthy, N. S., Allan, S. M., Chandler, D., Jablensky, A., & Morar, B. (2016). Integrity of genome-wide genotype data from low passage lymphoblastoid cell lines. Genomics Data, 9, 18-21.

McOmish, C. E., Pavey, G., Gibbons, A., Hopper, S., Udawela, M., Scarr, E., & Dean, B. (2016). Lower [3H] LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia. Journal of Affective Disorders, 190, 241-248.

McOmish, C., Pavey, G., Mclean, C., Horne, M., Dean, B., & Scarr, E. (2016). Muscarinic receptor binding changes in postmortem Parkinson’s disease. Journal of Neural Transmission, 124(2), 227-236.

Michalak, E.E., Jones, S., Lobban, F., Algorta, G.P., Barnes, S.J., Berk, L., Berk, M., Hole, R., Lapsley, S., Maxwell, V. & Milev, R. (2016). Harnessing the potential of community-based participatory research approaches in bipolar disorder. International Journal of Bipolar Disorders, 4(1), 1-9.

Morgan, V. A., Morgan, F., Galletly, C., Valuri, G., Shah, S., & Jablensky, A. (2016). Sociodemographic, clinical and childhood correlates of adult violent victimisation in a large, national survey sample of people with psychotic disorders. Social Psychiatry and Psychiatric Epidemiology, 51(2), 269-279.

Morris, G., & Berk, M. (2016). The Putative Use of Lithium in Alzheimer’s Disease. Curr Alzheimer Res, 13(8) 853-861.

Morris, G., Berk, M., Galecki, P., Walder, K., & Maes, M. (2016). The neuro-immune pathophysiology of central and peripheral fatigue in systemic immune-inflammatory and neuro-immune diseases. Molecular Neurobiology, 53(2), 1195-1219.

Mostaid, M. S., Lloyd, D., Liberg, B., Sundram, S., Pereira, A., Pantelis, C., . . . Bousman, C. A. (2016). Neuregulin-1 and schizophrenia in the genome-wide association study era. Neuroscience & Biobehavioral Reviews, 68, 387-409.

O’Neil A., Fisher A.J., Kibbey K.J., Jacka F.N., Kotowicz M.A., Williams L.J., Stuart A.L., Berk M., Lewandowski P.A., Taylor C.B., & Pasco J.A. (2016). Depression is a risk factor for incident coronary heart disease in women: An 18-year longitudinal study. Journal of Affective Disorders, 196, 117-124.

O’Neil A., Fisher A.J., Kibbey K.J., Jacka F.N., Kotowicz M.A., Williams L.J., Stuart A.L., Berk M., Lewandowski P.A., Atherton J.J., & Taylor C.B. (2016). The addition of depression to the Framingham Risk Equation model for predicting coronary heart disease risk in women. Preventive Medicine, 87, 115-120.

Oldis M., Murray G., Macneil C.A., Hasty M.K., Daglas R., Berk M., Conus P., & Cotton S.M. (2016). Trajectory and predictors of quality of life in first episode psychotic mania. Journal of Affective Disorders, 195, 148-155.

Panton, K. R., Badcock, D. R., & Badcock, J. C. (2016). A Metaanalysis of Perceptual Organization in Schizophrenia, Schizotypy, and Other High-Risk Groups Based on Variants of the Embedded Figures Task. Frontiers in Psychology, 7.

Passos, I. C., Mwangi, B., Vieta, E., Berk, M., & Kapczinski, F. (2016). Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatr Scand, 1, 13.

Polanco, J. C., Scicluna, B. J., Hill, A. F., & Götz, J. (2016). Extracellular vesicles isolated from the brains of rTg4510 mice seed tau protein aggregation in a threshold-dependent manner. Journal of Biological Chemistry, 291(24), 12445-12466.

Quek, C., Bellingham, S. A., Jung, C., Scicluna, B. J., Shambrook, M. C., Sharples, R. A., . . . Hill, A. F. (2016). Defining the purity of exosomes required for diagnostic profiling of small RNA suitable for biomarker discovery. RNA Biology, 14(2), 245-258.

Rainey-Smith, S. R., Brown, B. M., Sohrabi, H. R., Shah, T., Goozee, K. G., Gupta, V. B., & Martins, R. N. (2016). Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. British Journal of Nutrition, 115(12), 2106-2113.

Rajasekaran, A., Shivakumar, V., Kalmady, S. V., Narayanaswamy, J. C., Subbana, M., Venugopal, D., . . . Debnath, M. (2016). The impact of HLA-G 3′ UTR variants and sHLA-G on risk and clinical correlates of schizophrenia. Human Immunology, 77(12), 1166-1171.

Rapado-Castro, M., Dodd, S., Bush, A. I., Malhi, G. S., Skvarc, D. R., On, Z. X., . . . Dean, O. M. (2016). Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychological Medicine, 47(05), 866-876.

Ratheesh, A., Cotton, S.M., Davey, C.G., Adams, S., Bechdolf, A., Macneil, C., Berk, M. & McGorry, P.D.  (2016). Ethical considerations in preventive interventions for bipolar disorder. Early Intervention in Psychiatry.

Roberts, B. R., Doecke, J. D., Rembach, A., Yévenes, L. F., Fowler, C. J., Mclean, C. A., . . . Hare, D. J. (2016). Rubidium and potassium levels are altered in Alzheimer’s disease brain and blood but not in cerebrospinal fluid. Acta Neuropathologica Communications, 4(1).

Rosenblat, J.D., Kakar, R., Berk, M., Kessing, L.V., Vinberg, M., Baune, B.T., Mansur, R.B., Brietzke, E., Goldstein, B.I. & McIntyre, R.S. (2016). Anti‐inflammatory agents in the treatment of bipolar depression: a systematic review and meta‐analysis. Bipolar Disorders, 18(2), 89-101.

Rowe, C.C., Jones, G., Dore, V., Pejoska, S., Margison, L., Mulligan, R.S., Chan, J.G., Young, K. & Villemagne, V.L. (2016). Standardized Expression of 18F-NAV4694 and 11C-PiB beta-Amyloid PET Results with the Centiloid Scale. Journal of Nuclear Medicine, jnumed-115.

Salagre, E., Fernandes, B. S., Dodd, S., Brownstein, D. J., & Berk, M. (2016). Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. Journal of Affective Disorders, 200, 235-242.

Sarris, J., Murphy, J., Mischoulon, D., Papakostas, G. I., Fava, M., Berk, M., & Ng, C. H. (2016). Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. The American Journal of Psychiatry,173(6), 575.

Scarr, E., Udawela, M., Greenough, M.A., Neo, J., Seo, M.S., Money, T.T., Upadhyay, A., Bush, A.I., Everall, I.P., Thomas, E.A. & Dean, B. (2016). Increased cortical expression of the zinc transporter SLC39A12 suggests a breakdown in zinc cellular homeostasis as part of the pathophysiology of schizophrenia. npj Schizophrenia, 2, 16002.

Scarr, E., Udawela, M., Thomas, E. A., & Dean, B. (2016). Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor. Molecular Psychiatry.

Scarr, E., Mclean, C., & Dean, B. (2016). Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer’s disease. Journal of Neural Transmission, 124(3), 273-284.

Scarr, E., Seo, M. S., Aumann, T. D., Chana, G., Everall, I. P., & Dean, B. (2016). The distribution of muscarinic M1 receptors in the human hippocampus. Journal of Chemical Neuroanatomy, 77, 187-192.

Skvarc, D.R., Dean, O.M., Byrne, L.K., Gray, L.J., Ives, K., Lane, S.E., Lewis, M., Osborne, C., Page, R., Stupart, D. & Turner, A.  (2016). The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial. Trials, 17(1), 395.

Slyepchenko, A., Maes, M., Köhler, C.A., Anderson, G., Quevedo, J., Alves, G.S., Berk, M., Fernandes, B.S. & Carvalho, A.F. (2016). T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model. Neuroscience & Biobehavioral Reviews, 64, 83-100.

Stange, J. P., Kleiman, E. M., Sylvia, L. G., Magalhães, P. V. D. S., Berk, M., Nierenberg, A. A., & Deckersbach, T. (2016). Specific mood symptoms confer risk for subsequent suicidal ideation in bipolar disorder with and without suicide attempt history: multi‐wave data from STEP‐BD. Depression and Anxiety, 33(6), 464-472.

Stange, J.P., Sylvia, L.G., da Silva Magalhães, P.V., Miklowitz, D.J., Otto, M.W., Frank, E., Yim, C., Berk, M., Dougherty, D.D., Nierenberg, A.A. & Deckersbach, T. (2016). Affective instability and the course of bipolar depression: results from the STEP-BD randomised controlled trial of psychosocial treatment. The British Journal of Psychiatry, 208(4), 352-358.

Sun, J., Walker, A. J., Dean, B., Buuse, M. V., & Gogos, A. (2016). Progesterone: The neglected hormone in schizophrenia? A focus on progesterone-dopamine interactions. Psychoneuroendocrinology, 74, 126-140.

Talarowska, M., Berk, M., Maes, M., & Gałecki, P. (2016). Autobiographical memory dysfunctions in depressive disorders. Psychiatry and Clinical Neurosciences, 70(2), 100-108.

Tamano, H., Ide, K., Adlard, P. A., Bush, A. I., & Takeda, A. (2016). Involvement of hippocampal excitability in amyloid β-induced behavioral and psychological symptoms of dementia. The Journal of Toxicological Sciences41(4), 449-457.

Ugalde, C. L., Finkelstein, D. I., Lawson, V. A., & Hill, A. F. (2016). Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers. Journal of Neurochemistry, 139(2), 162-180.

Veerabhadrappa, R., Lim, C. P., Nguyen, T. T., Berk, M., Tye, S. J., Monaghan, P., . . . Bhatti, A. (2016). Unified selective sorting approach to analyse multi-electrode extracellular data. Scientific Reports, 6(1).

Villemagne, V. L., Okamura, N., & Rowe, C. C. (2016). Untangling tau imaging. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 4, 39-42.

Vogel, R., Coumans, F. A., Maltesen, R. G., Böing, A. N., Bonnington, K. E., Broekman, M. L., . . . Pedersen, S. (2016). A standardized method to determine the concentration of extracellular vesicles using tunable resistive pulse sensing. Journal of Extracellular Vesicles, 5(1), 31242.

Waterreus, A., Di Prinzio, P., Watts, G. F., Castle, D., Galletly, C., & Morgan, V. A. (2016). Metabolic syndrome in people with a psychotic illness: is cannabis protective?Psychological Medicine, 46(8), 1651.

Williams, L. J., Pasco, J. A., Hodge, J. M., & Berk, M. (2016). Is there a nexus between mental and bone health?. Australian and New Zealand Journal of Psychiatry, 0004867416652737.

Williams, L. J., Pasco, J. A., Jackson, H., Kiropoulos, L., Stuart, A. L., Jacka, F. N., & Berk, M. (2016). Depression as a risk factor for fracture in women: A 10 year longitudinal study. Journal of Affective Disorders, 192, 34-40.

Williams, L.J., Pasco, J.A., Mohebbi, M., Jacka, F.N., Stuart, A.L., Venugopal, K., O’Neil, A. & Berk, M. (2016). Statin and Aspirin Use and the Risk of Mood Disorders among Men. International Journal of Neuropsychopharmacology, pyw008.

Xu, H., Perreau, V. M., Dent, K. A., Bush, A. I., Finkelstein, D. I., & Adlard, P. A. (2016). Iron Regulates Apolipoprotein E Expression and Secretion in Neurons and Astrocytes. Journal of Alzheimer’s disease: JAD, 51(2), 471-487.

Yang, P.H., Zhu, J.X., Huang, Y.D., Zhang, X.Y., Lei, P., Bush, A.I., Xiang, Q., Su, Z.J. and Zhang, Q.H. (2016). Human Basic Fibroblast Growth Factor Inhibits Tau Phosphorylation via the PI3K/Akt-GSK3β Signaling Pathway in a 6-Hydroxydopamine-Induced Model of Parkinson’s Disease. Neurodegenerative Diseases, 16(5-6), 357-369.


Adlard, P.A., Parncutt, J., Lal, V., James, S., Hare, D., Doble, P., Finkelstein, D.I. & Bush, A.I. (2015). Metal chaperones prevent zinc-mediated cognitive decline. Neurobiology of disease, 81, 196-202.

Aggarwal, S., Berk, M., Taljard, L., & Wilson, Z. (2015). South African adolescents’ beliefs about depression. International Journal of Social Psychiatry, 0020764015618226.

Badcock, J. C., Shah, S., Mackinnon, A., Stain, H. J., Galletly, C., Jablensky, A., & Morgan, V. A. (2015). Loneliness in psychotic disorders and its association with cognitive function and symptom profile. Schizophrenia Research, 169(1), 268-273.

Badcock, J.C., Clark, M.L., Pedruzzi, R.A., Morgan, V.A. & Jablensky, A. (2015). Intact speed of processing in a community-based sample of adults with high schizotypy: A marker of reduced psychosis risk?. Psychiatry Research, 228(3), 531-537.

Berk M, Nierenberg AA. (2015) Three paths to drug discovery in psychiatryAmerican Journal of Psychiatry172(5), 412-414.

Berk, M. (2015). The Classification of Biomarkers. JAMA psychiatry, 72(10), 1056-1057.

Bigdeli, T. B., Ripke, S., Bacanu, S., Lee, S. H., Wray, N. R., Gejman, P. V., . . . Fanous, A. H. (2015). Genome-wide association study reveals greater polygenic loading for schizophrenia in cases with a family history of illness. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 171(2), 276-289.

Callaly, E., Walder, K., Morris, G., Maes, M., Debnath, M., & Berk, M. (2015). Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy. Mini Reviews in Medicinal Chemistry, 15(5), 355-365.

Chatterjee P, Gupta VB, Fagen AM, Jasielec MS, Xiong C, Sohrabi HR, Dhaliwal S, Taddei K, Bourgeat P, Brown BM, Benzinger T, Bateman RJ, Morris JC, Martins RN et al (2015). Decreased platelet APP isoform ratios in autosomal dominant Alzheimer’s disease: baseline data from a DIAN cohort subset. 12: 157-164.

Cropley, V.L., Scarr, E., Fornito, A., Klauser, P., Bousman, C.A., Scott, R., Cairns, M.J., Tooney, P.A., Pantelis, C. & Dean, B. (2015). The effect of a muscarinic receptor 1 gene variant on grey matter volume in schizophrenia. Psychiatry Research: Neuroimaging, 234(2), 182-187.

Daglas, R., Allott, K., Yücel, M., Pantelis, C., Macneil, C.A., Berk, M. & Cotton, S.M. (2015). The trajectory of cognitive functioning following first episode mania: A 12-month follow-up study. Australian and New Zealand Journal of Psychiatry, 0004867415622272.

Dash, S., Clarke, G., Berk, M., & Jacka, F. N. (2015). The gut microbiome and diet in psychiatry. Current Opinion in Psychiatry, 28(1), 1-6.

de Souza Gomes, J.A., de Souza, G.C., Berk, M., Cavalcante, L.M., de Sousa, F.C.F., Budni, J., de Lucena, D.F., Quevedo, J., Carvalho, A.F. & Macêdo, D. (2015). Antimanic-like activity of candesartan in mice: Possible involvement of antioxidant, anti-inflammatory and neurotrophic mechanisms. European Neuropsychopharmacology, 25(11), 2086-2097.

Dean, B., & Scarr, E. (2015). Possible involvement of muscarinic receptors in psychiatric disorders: A focus on schizophrenia and mood disordersCurrent molecular medicine.

Dean, B., Hopper, S., Conn, P. J., & Scarr, E. (2015). Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations. Neuropsychopharmacology, 41(6), 1620-1628.

Dean, B., Thomas, N., Lai, C. Y., Chen, W. J., & Scarr, E. (2015). Changes in cholinergic and glutamatergic markers in the striatum from a sub-set of subjects with schizophrenia. Schizophrenia Research, 169(1), 83-88.

Dean, O.M., Mancuso, S.G., Bush, A.I., Copolov, D., Do, K.Q., Cuénod, M., Conus, P., Rossell, S.L., Castle, D.J. & Berk, M. (2015). Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. Psychiatry research, 230(3), 982.

Fernandes, B.S., Molendijk, M.L., Köhler, C.A., Soares, J.C., Leite, C.M.G., Machado-Vieira, R., Ribeiro, T.L., Silva, J.C., Sales, P.M., Quevedo, J. & Oertel-Knöchel, V. (2015). Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Medicine, 13(1), 1-22.

Finkelstein, D.I., Hare, D.J., Billings, J.L., Sedjahtera, A., Nurjono, M., Arthofer, E., George, S., Culvenor, J.G., Bush, A.I. & Adlard, P.A (2015). Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice. ACS chemical neuroscience, 7(1), 119-129.

Ghanizadeh, A., Singh, A. B., Berk, M., & Torabi-Nami, M. (2015). Homocysteine as a potential biomarker in bipolar disorders: a critical review and suggestions for improved studies. Expert Opinion on Therapeutic Targets, 19(7), 927-939.

Gogos, A., Sbisa, A. M., Sun, J., Gibbons, A., Udawela, M., & Dean, B. (2015). A role for estrogen in schizophrenia: clinical and preclinical findings. International Journal of Endocrinology, 2015, 615356-615356.

Gupta VB, Wilson AC, Burnham S, Hone E, Pedrini S, Laws SM, Lim WL, Rembach A, Rainey-Smith S, Ames D, Cobiac L, Macaulay SL, Masters CL, Rowe CC, Bush AI, Martins RN; AIBL Research Group (2015). Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohortAlzheimer’s research & therapy7, 1-9.

Hamazaki K, Maekawa M, Toyota T, Dean B, Hamazaki T, Yoshikawa T (2015) Fatty acid composition of the postmortem prefrontal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder.  Psychiatry research227(2), 353-359.

Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ, Grimm R, Doble PA, Cherny RA, Masters CL, Bush AI, Roberts BR (2015). Decreased plasma iron in Alzheimer’s disease is due to transferrin desaturationACS chemical neuroscience.

Hayley AC, Williams LJ, Venugopal K, Kennedy GA, Berk M, Pasco JA (2015). The relationships between insomnia, sleep apnoea and depression: Findings from the American National Health and Nutrition Examination Survey, 2005-2008. Australian and New Zealand journal of psychiatry49(2), 156-170.

Hubbard, L., Tansey, K.E., Rai, D., Jones, P., Ripke, S., Chambert, K.D., Moran, J.L., McCarroll, S.A., Linden, D.E., Owen, M.J. & O’Donovan, M.C. (2015). Evidence of common genetic overlap between schizophrenia and cognition. Schizophrenia Bulletin, 42(3), 832-842.

Jablensky, A (2015). Schizophrenia or Schizophrenias? The Challenge of Genetic Parsing of a Complex DisorderAm J Psychiatry172(2).Dipnall JF, Pasco JA, Meyer D, Berk M, Williams LJ, Dodd S, Jacka FN (2015). The association between dietary patterns, diabetes and depressionJ Affect Disord 174, 215-224.

Kim, S.W., Bae, K.Y., Kim, J.M., Shin, I.S., Hong, Y.J., Ahn, Y., Jeong, M.H., Berk, M. & Yoon, J.S. (2015). The use of statins for the treatment of depression in patients with acute coronary syndrome. Translational Psychiatry, 5(8), e620.

Lei, P., Ayton, S., Appukuttan, A.T., Volitakis, I., Adlard, P.A., Finkelstein, D.I. & Bush, A.I. (2015). Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiology of disease, 81, 168-175.

Li, X., Lei, P., Tuo, Q., Ayton, S., Li, Q.X., Moon, S., Volitakis, I., Liu, R., Masters, C.L., Finkelstein, D.I. & Bush, A.I. (2015). Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of β-Amyloid Toxicity and Are Mediated by Tau. Neurotherapeutics, 12(4), 862-873.

Liang, S.H., Southon, A.G., Fraser, B.H., Krause-Heuer, A.M., Zhang, B., Shoup, T.M., Lewis, R., Volitakis, I., Han, Y., Greguric, I., Bush, A.I.*, & Vasdev, N (2015). Novel fluorinated 8-hydroxyquinoline based metal ionophores for exploring the metal hypothesis of Alzheimer’s disease. ACS medicinal chemistry letters, 6(9), 1025-1029. *co-senior authors.

Lim YY, Villemagne VL, Pietrzak RH, Ames D, Ellis KA, Harrington K, Syner PJ, Martins RN, Masters CL, Rowe CC, Maruff P et al (2015). APOE E4 moderates amyloid-related memory decline in preclinical Alzheimer’s disease. Neurology of Aging 36: 1239-1244

Maes M, Nowak G, Caso JR, Leza JC, Song C, Kubera M, Klein H, Galecki P, Noto C, Glaab E, Balling R, Berk M (2015) Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. Molecular neurobiology, 1-9.

Malhi, G. S., & Berk, M. (2015). Depolarising bipolarity: Clinical considerations. Australian and New Zealand Journal of Psychiatry, 49(9), 767-769.

Morris G, Berk M (2015) The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disordersBMC medicine13(1), 68.

Morris G, Berk M, Walder K, Maes M (2015) The Putative Role of Viruses, Bacteria, and Chronic Fungal Biotoxin Exposure in the Genesis of Intractable Fatigue Accompanied by Cognitive and Physical Disability. Mol Neurobiol. 2015 Jun 17. [Epub ahead of print]

Morris, G., Walder, K., Puri, B. K., Berk, M., & Maes, M. (2015). The deleterious effects of oxidative and nitrosative stress on palmitoylation, membrane lipid rafts and lipid-based cellular signalling: new drug targets in neuroimmune disorders. Molecular Neurobiology, 1-21.

Nunes SO, Piccoli de Melo LG, Pizzo de Castro MR, Barbosa DS, Vargas HO, Berk M, Maes M (2015) Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorderJournal of Affective Disorders 172(2015)55–62.

Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, Sarris J (2015) N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review. Clinical Psychopharmacology and Neuroscience13(1), 12.

Opie, R. S., Segal, L., Jacka, F. N., Nicholls, L., Dash, S., Pizzinga, J., & Itsiopoulos, C. (2015). Assessing healthy diet affordability in a cohort with major depressive disorders. Journal of Public Health and Epidemiology, 7(5), 159-169.

Panizzutti B., Gubert C., Schuh A.L., Ferrari P., Bristot G., Fries G.R., Massuda R., Walz J., Rocha N.P., Berk M., & Teixeira A.L. (2015). Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: An accelerated aging biomarker?. Journal of Affective Disorders, 182, 64-69.

Paul, B., Hare, D.J., Bishop, D.P., Paton, C., Cole, N., Niedwiecki, M.M., Andreozzi, E., Vais, A., Billings, J.L., Bray, L., Bush, A.I., McColl, G., Roberts, B.R., Adlard, P.A., Finkelstein, D.I., Hellstrom, J., Hergt, J.M., Woodhead, J.D., & Doble, P.A.  (2015). Visualising mouse neuroanatomy and function by metal distribution using laser ablation-inductively coupled plasma-mass spectrometry imaging. Chemical Science, 6(10), 5383-5393.

Pizzo de Castro MR, Vargas Nunes SO, Guembarovski RL, Ariza CB, Oda JM, Vargas HO, Piccoli de Melo LG, Watanabe MA, Berk M, Maes M (2015) STin2 VNTR polymorphism is associated with comorbid tobacco use and mood disordersJournal of Affective Disorders, 172: 347-354.

Power, B. D., Dragovic, M., Badcock, J. C., Morgan, V. A., Castle, D., Jablensky, A., & Stefanis, N. C. (2015). No additive effect of cannabis on cognition in schizophrenia. Schizophrenia Research, 168(1), 245-251.

Ratheesh, A., Cotton, S.M., Betts, J.K., Chanen, A., Nelson, B., Davey, C.G., McGorry, P.D., Berk, M. & Bechdolf, A. (2015). Prospective progression from high-prevalence disorders to bipolar disorder: Exploring characteristics of pre-illness stages. Journal of Affective Disorders, 183, 45-48.

Rembach A, Stingo FC, Peterson C, Vannucci M, Do KA, Wilson WJ, Macaulay SL, Ryan TM, Martins RN, Ames D, Masters CL, Doecke JD, et al (2015) Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer’s disease. J Alzheimer’s Dis, 44:917-925.

Sarris, J., Oliver, G., Camfield, D.A., Dean, O.M., Dowling, N., Smith, D.J., Murphy, J., Menon, R., Berk, M., Blair-West, S. & Ng, C.H (2015). N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: A 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs, 29(9), 801-809.

Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Shitij Kapur S, Möller H-J, Dean B (2015) Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a report of the 2013 CINP Think-Tank.  International Journal of Neuropsychopharmacology, pyv042.

Shibata, N., Nagata, T., Tagai, K., Shinagawa, S., Ohnuma, T., Kawai, E., Kasanuki, K., Shimazaki, H., Toda, A., Tagata, Y. & Nakada, T. (2015). Association between the catechol‐O‐methyltransferase polymorphism Val158Met and Alzheimer’s disease in a Japanese population. International Journal of Geriatric Psychiatry, 30(9), 927-933.

Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R (2015) Clinical Trials of N-acetylcysteine in Psychiatry and Neurology: A Systematic Review. Neuroscience & Biobehavioral Reviews.

Smesny, S., Milleit, B., Schaefer, M.R., Hipler, U.C., Milleit, C., Wiegand, C., Hesse, J., Klier, C.M., Holub, M., Holzer, I. & Berk, M. (2015). Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), 101, 15-21.

Talarowska M, Szemraj J, Berk M, Maes M, Gałecki P (2015) Oxidant/antioxidant imbalance is an inherent feature of depression.  BMC psychiatry15(1), 71.

Thai, C., Lim, Y.Y., Villemagne, V.L., Laws, S.M., Ames, D., Ellis, K.A., Rainey-Smith, S.R., Martins, R.N., Masters, C.L., Rowe, C.C. & Maruff, P. (2015). Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months. PloS one, 10(10), e0139082

Thibaut, F., Boutros, N.N., Jarema, M., Oranje, B., Hasan, A., Daskalakis, Z.J., Wichniak, A., Schmitt, A., Riederer, P. & Falkai, P. (2015). Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology. The World Journal of Biological Psychiatry, 16(5), 280-290.

Udawela, M., Money, T. T., Neo, J., Seo, M. S., Scarr, E., Dean, B., & Everall, I. P. (2015). SELENBP1 expression in the prefrontal cortex of subjects with schizophrenia. Translational Psychiatry, 5(8), e615.

Vargas Nunes SO, Pizzo de Castro MR, Moreira EG, Guembarovski RL, Barbosa DS, Vargas HO, Piccoli de Melo LG, Bortolasci CC, Watanabe MA, Dodd S, Berk M, Maes M (2015) Association of paraoxonase (PON)1 activity, glutathione S-transferase GST T1/M1 and STin.2 polymorphisms with comorbidity of tobacco use disorder and mood disordersNeuroscience Letters 2015; 585:132–137.

Waterdrinker A, Berk M, Venugopal K, Rapado-Castro M, Turner A, Dean OM (2015) Effects of N-Acetyl cysteine on suicidal ideation in bipolar depression. J Clin Psychiatry. 2015 May;76(5):e665.

Xu, H., Gupta, V.B., Martins, I.J., Martins, R.N., Fowler, C.J., Bush, A.I., Finkelstein, D.I. & Adlard, P.A. (2015). Zinc affects the proteolytic stability of Apolipoprotein E in an isoform-dependent way. Neurobiology of disease, 81, 38-48.

Yui, K., Sato, A., & Imataka, G. (2015). Mitochondrial dysfunction and its relationship with mTOR signaling and oxidative damage in autism spectrum disorders. Mini reviews in medicinal chemistry, 15(5), 373-389.


Aish PR, Catterjee P, Verdile G, Gupta VB, Trengove RD, Martins RN (2014) Clearing the amyoid in Alzheimer’s: progress towards earlier diagnosis and effective treatments – an update for cliniciansNeurodegenerative disease management 4: 363-378.

Anderson G, Berk M, Dean O, Moylan S, Maes M (2014) Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs 28(1): 1-10.

Anderson G, Kubera M, Duda W, Lason W, Berk M, Maes M (2014) Increased IL-6 trans-signaling in depression: focus on the tryptophan catbolite pathway, melatonin and neuroprogression. Pharmacological Reports 65(6): 1647-54.

Aydemir O, Cubukçuoğlu Z, Erdin S, Taş C, Onur E, Berk M (2014) Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. Rev Bras Psiquiatr. 2014 Dec;36(4):293-7.

Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, Hewitt K, Moss K, Allwang C, Schapkaitz I, Robbins J, Cobb H, Ng F, Dodd S, Bush AI, Malhi GS (2014) The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Psychiatry 75(6): 628-36.

Bortolasci CC, Vargas HO. Souza-Nogueira A, Barbosa DS, Moreira EG, Nunes SO, Berk M, Dodd S, Maes M (2014) Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. Journal of Affective Disorders 159: 23-30.

Bortolasci CC, Vargas HO, Souza-Nogueira A, Gastaldello Moreira E, Vargas Nunes SO, Berk M, Dodd S, Barbosa DS, Maes M (2014) Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity. Redox Report 2014; 19(6): 232-241.

Bousman CA, Sarris J, Won ES, Chang HS, Singh A, Lee HY, Ham BJ, Tan CH, Lee MS, Ng CH (2014) Escitalopram Efficacy in Depression – A Cross-Ethnicity Examination of the Serotonin Transporter Promoter Polymorphism. Psychopharmacol 2014;34(5): 00-00.

Brown BB, Bourgeat P, Peiffer JJ, Burnham S, Laws SM, Rainey-Smith SR, Bartres-Faz D, Villemagne VL, Taddei K, Rembach A, Bush A, Ellis KA, Macaulay SL, Rowe CC, Ames D, Masters CL, Maruff P, Martins RN et al (2014) Influence of BDNF Val66Met on the relationship between physical activity and brain volume. 83: 1345-1352.

Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke JD, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rembach A, Rowe C, Salvado O, Lance Macaulay S, Masters CL, Villemagne VL; Alzheimer’s Disease Neuroimaging Initiative; Australian Imaging, Biomarkers and Lifestyle Study Research Group (2014) A blood based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study. Molecular Psychiatry 19(4): 519-526.

Caine JM, Churches Q, Waddington L, Nigro J, Breheney K, Masters CL, Nuttall SD, Stretsov VA (2014) Design of non-aggregating variants of AB peptideBiochemical and Biophysical Research Communications 453: 449-454. 

Carvalho AF, Berk M, Hyphantis TN, McIntyre RS (2014) The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychotherapy and Psychomatics 83(2): 70-88.

Carvalho AF, Rocha DQ, McIntyre RS, Mesquita LM, Köhler CA, Hyphantis TN, Sales PM, Machado-Vieira R, Berk M (2014) Adipokines as emerging depression biomarkers: A systematic review and meta-analysis. J Psychiatr Res. 2014 Dec;59:28-37.

Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A, Martins RN, Rowe CC, Macaulay SL, Masters CL, Hill AF (2014). Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry.

Davis J, Maes M, Andreazza A, McGrath JJ, Tye SJ, Berk M (2014) Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol Psychiatry doi: 10.1038/mp.2014.139.

Dean B, Tawadros N, Suk Seo MS, Jeon WJ, Everall I, Scarr E, Gibbons A (2014) Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine. International Journal of Neuropsychopharmacology 17:895-906.

Dean OM, Turner A, Malhi GS, Ng C, Cotton S, Dodd S, Sarris J, Samuni Y , Tanious M, Dowling N, Waterdrinker A, Smith D, Berk M, (2014) Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. Revista Brasileira de Psiquiatria, (AHEAD), 00-00.

Debnath M, Berk M (2014) Th17 pathway mediated immunopathogenesis of schizophrenia: mechanisms and implications. Schizoph Bull, 40: 1412-1421.

Debnath M, Venkatasubramanian G, Berk M (2014) Fetal programming of schizophrenia: select mechanisms. Neurosci Biobehav Rev. 2014 Dec 10.

Deckersbach T, Peters AT, Sylvia L, Urdahl A, Magalhaes PV, Otto MW, Frank E, Miklowitz DJ, Berk M, Kinrys G, Nierenberg A (2014) Do comorbid anxiety disorders moderate the effects of psychotherapy for bipolar disorder? Results from STEP-BD. The American Journal of Psychiatry 171(2): 178-86.

Dipnall, JF, Berk, M, Jacka, FN, Williams, LJ, Dodd, S, & Pasco, JA (2014). Data Integration Protocol In Ten-steps (DIPIT): A new standard for medical researchers. Methods, 69(3), 237-246.

Faux NG, Rembach A, Wiley J, Ellis KA, Ames D, Fowler CJ, Martins RN, Pertile KK, Rumble RL, Trounson B, Masters CL, the AIBL Research Group, Bush AI (2014) An anemia of Alzheimer’s disease. Molecular Psychiatry doi:10.1038/mp.2013.178

Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW, Nardin P, Gonçalves CA (2014) Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry doi: 10.1038/mp.2014.117.

Graham KT, Martin-Iverson MT, Holmes NP, Jablensky A, Waters F (2014) Deficits in agency in schizophrenia and additional deficits in body image, body schema and internal timing in passivity symptoms Frontiers of Psychiatry Epub ahead of print 2014, doi: 10:3389/fpsyt.2014.00126.

Gusev A, Lee SH, Trynka G, Finucane H, Vilhjálmsson BJ, Xu H, Zang C, Ripke S, Bulik-Sullivan B, Stahl E; Kähler AK, Hultman CM, Purcell SM, McCarroll SA, Daly M, Pasaniuc B, Sullivan PF, Neale BM, Wray NR,Raychaudhuri S, Price AL; Schizophrenia Working Group of the Psychiatric Genomics Consortium; SWE-SCZ Consortium (2014). Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. The American Journal of Human Genetics, 95(5), 535-552.

Hare DJ, Lei P, Ayton S, Roberts BR, Grimm R, George JL, Bishop DP, Beavis AD, Donovan SJ, McColl G, Volitakis I, Masters CL, Adlard PA, Cherny RA, Bush AI, Finkelstein DI, Doble PA (2014) An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. Chemical Science 5: 2160-2169.

Hayley AC, Williams LJ, Kennedy GA, Berk M, Brennan SL, Pasco JA (2014). Excessive daytime sleepiness and body composition: a population-based study of adultsPloS one, 9(11), e112238.

Hayley AC, Williams LJ, Kennedy GA, Berk M, Brennan SL, Pasco JA (2014). Excessive daytime sleepiness and metabolic syndrome: a cross-sectional studyMetabolism, 64(2), 244-252.

Hung YH, Faux NG, Killilea DW, Yanjamin N, Firnkes S, Volitakis I, Ganio G, Walterfang M, Hastings C, Porter FD, Ory DS, Bush AI (2014) Altered transition metal homeostasis in Niemann-Pick disease, Type C1. Metallomics 6: 542-53.

Jablensky A, Waters F (2014) RDoC: a road to pathogenesis? World Psychiatry 2014, 13:43-44.

Jiang, Z, Du, C, Jablensky, A, Liang, H, Lu, Z, Ma, Y, & Teo, KL (2014). Analysis of Schizophrenia Data Using A Nonlinear Threshold Index Logistic Model. PloS one, 9(10), e109454.

Johnson P, Vandewater L, Wilson W, Maruff P, Savage G, Graham P, Macaulay LS, Ellis KA, Szoeke C, Martins RN, Rowe CC, Masters CL, Ames D, Zhang P (2014). Genetic algorithm with logistic regression for prediction of progression to Alzheimer’s disease. BMC bioinformatics, 15(Suppl 16), S11.

Kapczinski F, Magalhães PV, Balanzá-Martinez V, Dias VV, Frangou S, Gama CS, Gonzalez-Pinto A, Grande I, Ha K, Kauer-Sant’Anna M, Kunz M, Kupka R, Leboyer M, Lopez-Jaramillo C, Post RM, Rybakowski JK, Scott J, Strejilevitch S, Tohen M, Vazquez G, Yatham L, Vieta E, Berk M (2014) Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr Scand. 2014 Nov;130(5):354-63.

Kim SW, Schäfer MR, Klier CM, Berk M, Rice S, Allott K, Bartholomeusz CF, Whittle SL, Pilioussis E, Pantelis C, McGorry PD, Amminger GP (2014) Relationship between membrane fatty acids and cognitive symptoms and information processing in individuals at ultra-high risk for psychosis. Schizophr Res. 2014 Sep;158(1-3):39-44.

Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PF, Ames D, Ellis KA, Harrington K, Rembach A, Martins RN, Rowe CC, Masters CL, Maruff P (2014) APOE and BDNF polymorphisms moderate amyloid B-related cognitive decline in pre-clinical Alzheimer’s disease. Molecular Psychiatry.

Maes M, Anderson G, Kubera M, Berk M (2014) Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opinion on Therapeutic Targets 18(5): 495-512.

Malhi GS, Berk M (2014) Diagnosing bipolar disorder: Defining thresholds and setting boundaries. Australian and New Zealand Journal of Psychiatry 48(500): 500-504.

Maruff P, Masters C, Ames D, Bush A, Rowe C, Villemagne V, Ellis K, Harrington K, Lim YY (2014) Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer’s disease: A preliminary study. PLoS One 9: e86498-e86502.

McGorry P, Keshavan M, Goldstone S, Amminger P, Allott K, Berk M, Lavoie S, Pantelis C, Yung A, Wood S, Hickie I (2014) Biomarkers and clinical staging in psychiatry. World Psychiatry. 2014 Oct;13(3):211-23.

Moore EM, Ames D, Mander AG, Carne RP, Brodaty H, Woodward MC, Boundy K, Ellis KA, Bush AI, Faux NG, Martins RN, Masters CL, Rowe CC, Szoeke C, Watters DA (2014) Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. Journal of Alzheimer’s Disease 39: 661-8.

Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Ellis KA, Bush AI, Faux NG, Watters DA (2014) Response to comment on Moore et al, Increased risk of cognitive impairment in patients with diabetes is associated with metformin, Diabetes care 36: 2981-2987. Diabetes Care 37: e151. doi: 10.2337/dc14-0278.

Morris G, Anderson G, Dean O, Berk M, Galecki P, Martin-Subero M, Maes M (2014) The glutathione system: a new drug target in neuroimmune disorders. Mol Neurobiol 50: 1059-1084.

Moylan S, Berk M, Dean OM. Samuni Y, Williams LJ, O’Neil A, Hayley AC, Pasco JA, Anderson G, Jacka FN, Maes M (2014) Oxidative & nitrosative stress in depression: Why so much stress? Neuroscience and Biobehavioral Reviews 45C: 46-62.

Nabavi SF, Turner A, Dean O, Sureda A, Mohammad S (2014) Post-stroke Depression Therapy: Where are we now? Current Neurovascular Research, 2014, 11, 00-00.

O’Neil A, Quirk SE, Housden S, Brennan SL, Williams LJ, Pasco JA, Berk M, Jacka FN (2014). Relationship between diet and mental health in children and adolescents: a systematic reviewAmerican journal of public health, 104(10), e31-e42.

Opazo CM, Greenough MA, Bush AI (2014) Copper: From neurotransmission to neuroproteostasis. Frontiers in Aging Neuroscience 6: 143.

Pietrzak RH, Lim YY, Ames D, Harrington K, Restrepo C, Martins RN, Rembach A, Laws SM, Masters CL, Villemagne VL, Rowe CC, Maruff P;Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group (2014). Trajectories of memory decline in preclinical Alzheimer’s disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiology of aging, 36 (3) (2015), pp. 1231–1238

Pizzo de Castro MR, Maes M1, Guembarovski RL, Ariza CB, Reiche EM, Vargas HO, Vargas MM, de Melo LG, Dodd S, Berk M, Watanabe MA, Nunes SO (2014) SLC6A4 STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: a case control study. BMC Genetics 2014, 15:78.

Quirk SE, El-Gabalawy R, Brennan SL, Bolton JM, Sareen J, Berk M, Chanen AM, Pasco JA, Williams LJ (2014). Personality disorders and physical comorbidities in adults from the United States: data from the National Epidemiologic Survey on Alcohol and Related ConditionsSocial psychiatry and psychiatric epidemiology, 1-14.

Quirk SE, El-Gabalawy R, Brennan SL, Bolton J, Sareen J, Berk M, Chanen A, Pasco JA, Williams LJ (2014). Personality disorders and physical comorbidities in adults from the United States: Data from the National Epidemiological Survey on Alcohol and Related Conditions. Social Psychiatry and Social Epidemiology, 1-14.

Rapado-Castro M, Berk M, Venugopal K, Bush AI, Dodd S, Dean OM (2014) Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 57:69-75.

Redlich C, Berk M, Williams LJ, Sundquist J, Sundquist K, Li X (2014). Statin use and risk of depression: a Swedish national cohort studyBMC psychiatry, 14(1), 348.

Rembach A, Hare DJ, Doecke JD, Burnham SC, Volitakis I, Fowler CJ, Cherny RA, McLean C, Grimm R, Martins R, Ames D, Masters CL, Bush AI, Roberts BR (2014) Decreased serum zinc is an effect of ageing and not Alzheimer’s disease. Metallomics 6: 1216-1219.

Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li Q-X, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KL, Szoeke C, Macaulay LS, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL (2014) Changes in plasma beta-amyloid in a longitudinal study of aging and Alzheimer’s disease. Alzheimer’s and Dementia 10(1): 53-61.

Rembach A, Watt AD, Wilson WJ, Rainey-Smith S, Ellis KA, Rowe CC, Villemagne VL, Macaulay SL, Bush AI, Martins RN, Ames D, Masters CL, Doecke JD, et al (2014). An increased neutrophil-lymphocyte ratio in Alzheimer’s disease is a function of age and is weakly correlated with neocortical amyloid accumulation. J Neuroimmunol, 273:65-71.

Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD, AIBL Research Group (2014) Plasma Aβ levels are significantly associated with a transition towards Alzheimer’s disease as measured by cognitive decline and change in neocortical amyloid burden. Journal of Alzheimer’s disease 40(1): 95-104.

Ripke S, … Jablensky A et al [multi-authored publication], Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature,511(7510), 421-427.

Sanna L, Stuart AL, Pasco JA, Jacka FN, Berk M, Maes M, O’Neil A, Paolo G, Williams LJ (2014) Atopic disorders and depression: Findings from a large, population-based study. Journal of Affective Disorders 155: 261-265.

Seo MS, Scarr E, Dean B (2014). An investigation of the factors that regulate muscarinic receptor expression in schizophrenia. Schizophrenia Research 158: 247-254.

Seo MS, Scarr E, Lai CY, Dean B (2014) Potential molecular and cellular mechanism of psychotropic drugs. 12: 94-110.

Singh AB, Bousman CA, Ng C, Berk M (2014) Antidepressant pharmacogenetics. Current Opinion in Psychiatry 27(1): 43-51.

Squitti R, Simonelli I, Ventriglia M, Siotto M, Pasqualetti P, Rembach A, Doecke J, Bush AI (2014) Meta-analysis of serum non-ceruloplasmin copper in Alzheimer’s disease. Journal of Alzheimer’s Disease 38(4): 809-22.

Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan V, (2014) The effect of drug use on the age at onset of psychotic disorders in an Australian cohort. Schizophrenia Research 2014, 156:211-216.

Vargas HO, Vargas Nunes SO, Barbosa DS, Vargas MM, Certari A, Dodd S, Venugopal K, Maes M, Berk M (2014) Castelli risk indexes 1 and 2 are higher in major depression but other characteristics of the metabolic syndrome are not specific to mood disorders. Life Sciences 102(1): 65-71.

Wang Y, Zhang H, Chai F, Liu X, Berk M (2014) The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 during myocardial ischemia/reperfusion in a model of rats with depression. BMC Psychiatry. 2014 Dec 4;14(1):349.

Wang Y, Zhang H, Tang S, Liu X, O’Neil A, Turner A, Chai F, Chen F, Berk M (2014) Assessing regional cerebral blood flow in depression using 320-slice computed tomography. PLoS One. 2014 Sep 24;9(9):e107735.


Wong BXW, Hung YH, Bush AI, Duce JA (2014) Metals and cholesterol: two sides of the same coin in Alzheimer’s disease pathology. Frontiers in Aging Neuroscience 6: 91.


Berk M, Berk L, Dodd S, Fitzgerald PB, de Castella AR, Filia S, Filia K, Brnabic AJM, Kelin K, Montgomery W, Kulkarni J, Stafford L (2013) The sick role, illness cognitions and outcomes in bipolar disorder. Journal of Affective Disorders, 146: 146-149.

Berk M, Jacka FN, Williams LJ, O’Neil A, Pasco J, Moylan S, Allen N, Stuart A, Hayley A, Byrne M, Maes M (2013) So depression is an inflammatory disease, but where does the inflammation come from? BMC Medicines, 11(1): 1-16.

Berk M, Malhi GS, Gray LJ, Dean OM (2013) The promise of N-acetylcysteine in psychiatry. Trends in Pharmacological Sciences 34(3):167-177.

Brown BM, Peiffer JJ, Taddei K, Lui JK, Laws SM, Gupta VB, Taddei T, Ward VK, Rodrigues MA, Burnham S, Rainey-Smith SR, Villemagne VL, Bush AI, Ellis KA, Masters CL, Ames D, Macaulay SL, Szoeke C, Rowe CC, Martins RN, and the AIBL Research Group (2013) Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Molecular Psychiatry 18, 875-881.

Chana G, Bousman CA, Money TT, Gibbons A, Gillett P, Dean B, Ian Paul Everall IP (2013) Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Frontiers in Cellular Neuroscience 7: 95.

Dean B, Moller H-J, Svensson TH, Geyer MA, Rujescu D, Scarr E, Millan MJ (2013) Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP think-tank. International Journal of Neuropyschopharmacology 17:137-148.

Ellis KA, Lim YY, Harrington K, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne VL, Maruff P (2013) Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta. Journal of Alzheimer’s Disease 34(4): 861-871.

Ellis KA, Szoeke C, Bush AI, Darby D, Graham PL, Lautenschlager NT, Macaulay SL, Martins RN, Maruff P, Masters CL, McBride SJ, Pike KE, Rainey-Smith SR, Rembach A, Robertson J, Rowe CC, Savage G, Villemagne VL, Woodward M, Wilson W, Zhang P, Ames D, and the AIBL research group (2013) Rates of diagnostic transition and cognitive change at 18 month follow up among 1112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). International Psychogeriatrics 26(4): 543-54.

Fernandes BS, Berk M, Turck CW. Steiner J, Goncalves CA (2013) Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Molecular Psychiatry 19: 750-751.

Frey BN, Andreazza AC, Frye MA, Goldstein BI, Malhi GS, Hall GB, Taylor VH, Fernandes BS, Kauer-Sant’Anna M, Dodd S, Lopez-Jaramillo C, Leboyer M, Frangou S Yatham LN, Berk M, Yound T, Kapczinski F (2013) Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Commitee. Australian and New Zealand Journal of Psychiatry, 47: 321-332.

Ghanizadeh A, Berk M (2013) Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia. Medical Gas Research 3(1): 11.

Gibbons AS, Scarr E, Boer S, Money T, Jeon W-J, Felder C, Dean B (2013) Widespread decreases in cortical muscarinic receptors in a sub-set of people with schizophrenia. International Journal of Neurospsychopharamcology, 16: 37-46.

Gupta VB, Sundaram R, Martins RN (2013) Multiplex biomarkers in blood. Alzheimer’s Research & Therapy, 5: 31.

Hare D, Grubman A, Ryan TM, Lothian A, Liddell JR, Grimm R, Matsuda T, Doble PA, Cherney RA, Bush AI, White AR, Masters CL, Roberts BR (2013) Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. Metallomics 5(12): 1656-1662.

Jeon WJ, Gibbons AS, Dean B (2013) The use of a modified [H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. Progress in neuro-psychopharmacology and biological psychiatry 47: 7-12.

Lauder S, Chester A, Castle D, Dodd S, Berk L, Klein B, Austin D, Gilbert M, Chamberlain JA, Murray G, White C, Piterman L, Berk M (2013) Development of an online intervention for bipolar disorder, Psychology, Health & Medicine, 18.

Laws SM, Doeke JD, Martins (2013) Blood-based biomarkers in Alzheimer’s disease: where are we now and where have we to go? – Reply. Neurology, 70: 133-134.

Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, Harrington KD, Bourgeat P, Salvado O, Darby D, Snyder PJ, Bush AI, Martins RN, Masters CL, Rowe CC, Nathan PJ, Maruff P, Australian Imaging Biomarkers and Lifestyle Study of Ageing research group (2013) BDNF Val66Met, AB amyloid, and cognitive decline in preclinical Alzheimer’s disease. Neurobiology of Aging 34: 2457-2464.

Lim YY, Jaeger J, Harrington K, Ashwood T, Ellis KA, Stöffler A, Szoeke C, Lachovitzki R, Martins RN, Villemagne VL, Bush AI Masters CL, Rowe CC, Ames D, Darby D, Maruff P (2013) Three month stability of the CogState brief battery in healthy older adults, mild cognitive impairment and Alzheimer’s disease: Results from the Australian Imaging, Biomarkers and Lifestyle – Rate of Change sub-study (AIBL-ROCS). Archives of Clinical Neuropsychology 28(4): 320-330.

Lothian A, Hare D, Masters C, Ryan T, Grimm R, Roberts BR (2013) Metalloproteomics: Principles, challenges and applications to neurodegeneration. Frontiers in Aging Neuroscience 5:35.

Moller M, Du Preez JL, Vilijoen FP, Berk M, Emsley R, Harvey BH (2013) N-Acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats. Metabolic Brain Disease 28(4): 687-96.

Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis KA, Bush AI, Faux NG, Martins R, Szoeke C, Rowe C, Watters DA; AIBL Investigators (2013). Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 36: 2981-87. Erratum in: Diabetes Care 36: 3850.

Morris G, Anderson G, Berk M, Maes M (2013) Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Molecular Neurobiology 48(3): 883-903.

Nisbet RN, Nuttall SD, Caine JM, Robert R, Hittaki M, Pearce LA, Davydova N, Masters CL, Varghese JN, Streltsov VA (2013) Structural studies of the tethered N-terminus of the Alzheimer’s disease AB peptide. Proteins: Structure, Function and Bioinformatics, 81: 1748-1758.

Peters C, Fernandez-Perez EJ, Burgos CF, Espinoza MP, Castillo C, Urrutia JC, Streltsov VA, Opazo C, Aguayo LG (2013) Inhibition of the synaptotoxicity induced by Aβ oligomers by a pentapeptide derived from the glycine zipper region of the Aβ peptide. Neurobiology of Aging 34(12): 2805-2814.

Ripke S et al. [including Jablensky A]. (2013) Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics, 45.10 (2013): 1150-1159.

Ripke S et al. [including Jablensky A] (2013).Genome-wide association analysis identifies 13 new risk loci for schizophreniaNature Genetics 45: 1150-1159.

Rembach A, Doecke JD, Roberts BR, Watt AD, Faux NG, Volitakis I, Pertile KK, Rumble RL, Trounson BO, Folwer CJ, Wilson W, Ellis KA, Martins RN, Rowe CC, Villemagne VL, Ames D, Masters CL, Bush AI (2013) Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 34:171-182

Rembach A, Ryan T, Roberts B, Doecke J, Wilson W, Watt A, Barnham K, Masters C (2013) Progress towards consensus biomarkers for Alzheimer’s disease: a review of peripheral–based analytes. Biomarkers in Medicine 7: 1-22.

Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R, Robins P, Tochon-Danguy H, O’Keefe G, Pike KE, Yates P, Szoeke C, Salvado O, Macaulay SL, O’Meara T, Head R, Cobiac L, Savage G, Martins R, Masters CL, Ames D, Villemagne VL (2013) Predicting Alzheimer’s disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageingAnnals of Neurology 74: 905-913.

Ryan TM, Caine J, Mertens HDT, Kirby N, Nigro J, Breheney K, Waddington LJ, Streltsov VA, Curtain C, Masters CL, Roberts BR (2013) Ammonium hydroxide treatment of Aβ produces an aggregate free solution suitable for biophysical and cell culture characterization. PeerJ, DOI 10.7717/peerj.73.

Sanna L, Stuart AL, Pasco JA, Kotowicz MA, Berk M, Girardi P, Brennan SL, Williams LJ (2013) Physical comorbidities in men with mood and anxiety disorders: a population-based study. BMC Medicine 11:110.

Scarr E, Craig JM, Cairns MJ, Seo MS, Galati JC, Beveridge NJ, Gibbons A, Juzva S, Weinrich B, Parkinson-Bates M, Carroll AP, Saffery R, Dean B (2013) Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA. Translational Psychiatry 3, e230.

Scarr E, Um JY, Cowie TF, Dean B (2013) Cholinergic muscarinic M4 receptor gene polymorphisms; a potential risk factor and pharmacogenomic marker for schizophrenia. Schizophrenia Research 146: 279-284.

Schork AJ et al. [including Jablensky A] (2013) All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. PLoS Genetics 9.4: e1003449.

Streltsov VA, Epa VC, James SA, Churches QI, Caine JM, Kenche VB, Barnham KJ (2013) Structural insights into the interaction of platinum-based inhibitors with the Alzheimer’s disease amyloid-β peptide. Chemical Communications 49: 11364-11366.

Sumani Y, Goldstein S, Dean OM, Berk M (2013) The chemistry and biological activities of Nacetylcysteine. Biochimica et Biophysica Acta 1830: 4117–4129.

Terwisscha van Scheltinga AF et al. [including Jablensky A] (2013) Genetic schizophrenia risk variants jointly modulate total brain and white matter volume. Biological Psychiatry 73: 525-531.

Vargas HO, Nunes SO, Pizzo de Castro M, Cristina Bortolasci C, Sabbatini Barbosa D, Kaminami Morimoto H, Venugopal K, Dodd S, Maes M, Berk M (2013) Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. Journal of Affective Disorders 150(3): 923-30.

Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins RN, Maruff P, Ames D, Rowe CC, Masters CL, for the Australian Imaging Biomarkers and Lifestyle Research Group (2013) Aβ deposition, neurodegeneration and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurology 12: 357-367.



Anderson G, Maes M, Berk M (2012) Biological underpinnings of the commonalities in depression, somatisation and chronic fatigue syndrome. Medical Hypotheses, 78: 752-753.

Anderson G, Maes M, Berk M (2012) Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization. Advances in Protein Chemistry and Structural Biology, 88: 27-48.

Anderson RJ, Frye MA, Lee KH, McGillivray JA, Berk M, Tye SJ (2012) Deep brain stimulation for treatment-resistant depression: efficacy, safety and mechanisms of action. Neuroscience and Biobehavioral Reviews, 36: 1920-1933.

Bauer M, Glenn T, Alda M, Andreassen OA, Ardau R, Berk M et al (2012) Impact of sunlight on the age of onset of bipolar disorder, 14: 654-663.

Bechdolf A, Ratheesh A, Wood J, Tecic T, Conus P, Nelson B, Cotton S, Chanen A, Amminger G, Ruhrmann S, Schultze-Lutte F, Klosterkotter J, Fusar Poli P, Yung AR, Berk M, McGorry PD (2012) Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder. 18: 358-375.

Bechdolf A, Wood SJ, Nelson B, Velakoulis D, Yucel M, Takahashi T, Yung AR, Berk M, Wong WT, Pantelis C, McGorry PD (2012) Amygdala and insula volumes prior to illness onset in bipolar disorder: a magnetic resonance imaging study. Psychiatry Research, 201: 34-39.

Berk M (2012) Is Australian psychiatry getting SHIP shape? Australian and New Zealand Journal of Psychiatry, 46: 801-802.

Berk M, Berk L, Davey CG, Moylan S, Giorlando F, Singh AB, Kalra H, Dodd S, Malhi GS (2012) Treatment of bipolar depression, MJA Open, 1: 32-35.

Berk M, Berk L, Dodd S, Jacka FN, Fitzgerald B, de Castella AR, Fillia S, Dillia K, Kulkarni J, Jackson HJ, Stafford L (2012) Psychometric properties of a scale to measure investment in the sick role: the Illness Cognitions Scale, Journal of Evaluation in Clinical Practice, 18: 360-364.

Berk M, Berk L, Udina M, Moylan S, Stafford L, Hallam K, Goldstone S, McGorry PD (2012) Palliative models of care for later stages of mental disorder: maximizing recovery, maintaining hope, and building morale, Australian and New Zealand Journal of Psychiatry, 46: 92-99.

Berk M, Dean OM, Cotton SM, Gama CS, Kapczinski F, Fernandes B, Kohlmann K, Jeavons S, Hewitt K, Moss K, Allwang C, Schapkaitz I, Cobb H, Bush AI, Dodd S, Malhi GS (2012) Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomised placebo controlled trial, BMC Medicine 10: 91.

Berk M, Jacka F (2012) Preventive strategies in depression: gathering evidence for risk factors and potential interventions. British Journal of Pharmacology, 201: 339-341.

Bromberg A, Lerer E, Udawela M, Scarr E, Dean B, Belmaker RH, Ebstein R, Agam G (2012) Nicotinamide-N-methyltransferase (NNMT) in schizophrenia: genetic association and decreased frontal cortex mRNA levels. International Journal of Neuropyschopharamcology, 15: 727-737.

Chetelat G, Rowe CC, Villemagne VL. (2012) Amyloid Imaging in Alzheimer’s Disease: Relationships to Memory Deficits, Brain Atrophy, and Hypometabolism. European Neurological Journal 4: 61-68.

Chetelat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, Rowe CC (2012) Relationships between memory performances and [beta]-amyloid deposition at different stages of Alzheimer’s disease. Neurodegenerative Diseases, 10: 141-144.

Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe CC (2012) Accelerated cortical atrophy in cognitively normal elderly with high [beta]-amyloid deposition. Neurology, 78: 477-484.

Conn CE, Darmanin C, Mulet X, Hawley A, Drummond CJ (2012) Effect of lipid architecture on cubic phase susceptibility to crystallisation screens. Soft Matter, 8: 6884-6896.

Conn CE, Darmanin C, Mulet X, LeCann S, Kirby N, Drummond CJ (2012) High-throughput analysis of the structural evolution of the monoolein cubic phase in situ under crystallogenesis conditions. Soft Matter, in print.

Cotton SM, Lambert M, Schimmelmann BG, Gleeson JFM, Berk M, Hides L, Chanen A, McGorry PD, Conus P (2012) Depressive symptoms in first episode schizophrenia spectrum disorder. Schizophrenia Research, 134: 20-26.

Darmanin C, Conn CE, Newman J, Mulet X, Seabrook SA, Liang Y-L, Hawley A, Kirby N, Varghese JN, Drummond CJ (2012) High-throughput production and structural characterisation of libraries of self-assembly lipidic cubic phase materials. ACS Combinatorial Science, 14: 247-252.

Dean B (2012) Editorial: Cholinergic muscarinic receptors: New opportunities as drug targets to treat psychiatric disorders. Future medicinal chemistry, 5: 1-3.

Dean B (2012) Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. Current Pharmaceutical Biotechnology, 13: 1563-1571.

Dean B (2012) Neurochemistry of schizophrenia and psychosis: the contribution of neuroimaging. Current topics in medicinal chemistry, 12: 2375-2392.

Dean OM, Bush AI, Berk M (2012) Translating the Rosetta stone of N-acetyl cysteine. Biological Psychiatry, 71: 935-996.

Dean OM, Bush AI, Copolov DL, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hun M, Berk M (2012) Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Psychiatry and Clinical Neurosciences, 66: 514-517.

Dean OM, Data-Franco J, Giorlando F, Berk M (2012) Minocycline: therapeutic potential in psychiatry. CNS Drugs, 26: 391-401.

Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, Minoshima S, Rowe CC, Sabri O, Seibyl J, Van Berckel BN, Wanner M (2012) SNM practice guideline for dopamine transporter imaging with 123O-Ioflupane SPECT. Protein Science, 20:457-464.

Doeke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, Alzheimer’s Disease Neuroimaging Initiative, Australian Imaging Biomarkers and Lifestyle Study of Ageing (2012) Blood-based protein biomarkers for diagnosis of Alzheimer’s disease. Archives of Neurology, 69: 1318-1325.

Epa V, Streltsov V, Varghese J (2012) Computational studies on the stability of C-terminal beta-amyloid dimer and mutants. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 8: 718.

Green MJ, Cairns MJ, Wu, J, Dragovic M, Jablensky A, Tooney PA, Scott RJ, Carr VJ (2012) Genome-wide supported variant MIR317 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. Molecular Psychiatry.

Jablensky A (2012) The disease entity in psychiatry: fact or fiction? Epidemiology and Psychiatric Services, 21: 255-264

Jacka FN, Berk (2012) Depression, diet and exercise. MJA Open, 1: 21-23.

Jacka FN, Maes M, Pasco JA, Williams LJ, Berk M (2012). Nutrient intakes and the common mental disorders in women. Journal of Affective Disorders. Epub ahead of publication.

Jacka FN, Pasco JA, Williams LJ, Mann N, Hodge A, Brazionis L, Berk M (2012). Red meat consumption and mood and anxiety disorders. Pyschotherapy and Pyschosomatics, 81: 196-198.

Macneil CA, Hallam K, Conus P, Henry L, Kader L, Berk M (2012) Are we missing opportunities for early intervention in bipolar disorder? Expert Review Neurotherapy, 12: 5-7.

Maes M, Berk M, Goehler L, Song C, Anderson G, Galecki P, Leonard B (2012) Depression and sickness behaviour are Janus-faced responses to shared inflammatory pathways. BMC Medicine, 29: 66.

Maes M, Fisar Z, Medina M, Scapagnini G, Nowak G, Berk M (2012) New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant and neuroprogressive pathways and new drug candidates- NRF2 activators and GSK-3 inhibitors. Inflammopharmcology, 20: 127-150.

Maes M, Kubera M, Leunis JC, Berk M (2012) Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased translocation or leaky gut. Journal of Affective Disorders.

Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E (2012) In depression, bacterial translocation may drive inflammatory responses directed against O&NS-damaged neoepitopes. Acta Psychiatrica Scandinavica.

Maes M, Kubera M, Mihaylova I, Geffard M, Galecki P, Leunis JC, Berk M (2012) Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. Journal of Affective Disorders

Maes M, Ringel K, Kubera M, Berk M, Rybakowski J (2012) Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. Journal of Affective Disorders., 136: 386-392.

Magalhaes PVS, Dean O, Andreazza AC, Berk M, Kapczinski F (2012) Adjunctive antioxidants for bipolar disorder (Protocol). Cochrane Review.

Magalhaes PV, Dean OM, Bush AI, Copolov DL, Weisinger D, Malhi GS, Kolmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M (2012) Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. Progress in Neuro-Psychophamacology and Brain Psychiatry, 37: 132-135.

Magalhaes PV, Dodd S, Nierenberg AA, Berk M (2012) Cumulative morbidity and prognostic staging of illness in the systematic treatment enhancement program for bipolar disorder (STEP-BD) Australian & New Zealand Journal of Psychiatry, 46: 1017-1018.

Magalhaes PV, Kapczinski F, Nierenberg AA, Deckersbach T, Weisinger D, Dodd S, Berk M (2012) Illness burder and medical comordibity in the systematic treatment enhancement program for bipolar disorder. Acta Psychiatrica Sandinavica, 125: 303-308.

Malhi GS, Bargh DM, McIntye R, Gitlin M, Frye MA, Bauer M, Berk M (2012) Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disorders, 14: 1-21.

Malhi GS, Berk M (2012) Is the safety of lithium no longer in the balance? Lancet, 379: 690-692.

Malhi GS, Tanious M, Das P, Berk M (2012) The science and practice of lithium therapy Australian New Zealand Journal of Psychiatry, 46: 192-211.

Macneil CA, Hasty M, Cotton S, Berk M, Hallam K, Kader L, McGorry P, Conus P (2012) Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18-month pilot study, Early Intervention in Psychiatry, 6: 380-388.

Markanday S, Data-Franco J, Dyson L, Murrant S, Arbuckle C, McGillvray J, Berk M (2012) Acceptance and commitment therapy for treatment-resistant depression. Bipolar Disorders, 46: 1198-1199.

Maud C, Berk M (2012) Neuropsychiatric presentation of Lyme disease in Australia Australian New Zealand Journal of Psychiatry.

McGorry PD, Berk M, Berk L, Goldstone S (2012) Commentary on ‘Palliative models of car for later stages of mental disorder: Maximising recovery, maintaining hope and building morale’, Australian New Zealand Journal of Pyschiatry, 46: 276-278.

Moylan S, Giorlando F, Nordfjaern T, Berk M (2012) The role of alprazolam for the treatment of panic disorder in Australia. Australian New Zealand Journal of Pyschiatry, 46: 212-224.

Moylan S, Maes M, Wray NR, Berk M (2012) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Molecular Psychiatry 18: 595-606.

Nunes SO, Vargas HO, Brum J, Prado E, Bargas MM, de Castro MR, Dodd S, Berk M (2012) A comparison of inflammatory markers in depressed and nondepressed smokers. Nicotine Tobacco Research, 14: 540-546.

Pasco JA, Jacka FN, Williams LJ, Evans-Cleverdon M, Brennan SL, Kotowicz MA, Nicholson GC, Ball MJ, Berk M (2012) Dietary selenium and major depression: a nested case-control study. Complementary Therapies in Medicine, 20: 119-193.

Sarris J, Moylan S, Camfield DA, Pase MP, Mischoulon D, Berk M, Jacka FN, Schweitzer I (2012) Complementary medicine, exercise, meditation, diet and lifestyle modification for anxiety disorders: a review of current evidence. Evidence-based complementary and alternative medicine.

Scarr E (2012) Muscarinic M1 receptor agonists: can they improve cognitive performance in humans? International Journal of Neuropyschophamacology.

Scarr E (2012) Muscarinic receptors: Their roles in disorders of the central nervous system and potential as therapeutic targets. CNS Neuroscience & Therapeutics, 18: 369-379.

Scarr E, Dean B (2012) Altered neuronal markers following treatment with mood stabliser and antipsychotic drugs indicate an increased likelihood of neurotransmitter release. Clinical Pyschopharmacology and Neuroscience, 10: 25-33.

Scarr E, Money TT, Pavey G, Neo J, Dean B (2012) Mu opioid receptor availability in people with psychiatric disorders who died by suicide: a case control study. BMC Pyschiatry 12: 126.

Scarr E, Sundram S, Dejo A, Cowie TF, Gibbons AS, Juva S, Mackinnon A, Wood SJ, Testa R, Pantelis C, Dean B (2012) Muscarinic M1 receptor sequence: Preliminary studies on its effects on cognition and expression. Schizophrenia Research, 138: 94-98.

Sona A, Zhang P, Ames D, Bush AI, Lautenschalger NT, Martins RN, Masters CL, Rowe CC, Szoeke C, Taddei K, Ellis KA and the AIBL Research Group (2012) Predictors of rapid cognitive decline in Alzheimer’s disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. International Psychogeriatrics, 24: 197-204.

Steinberg S et al. [including Jablensky A] (2012) Common variant at 16q11.2 conferring risk of psychosis. Molecular Psychiatry doi:10.1038/mp.2012.157

Streltsov VA, James S, de Jonge M, Howard D, Paterson D, Sankovich S, Caine J (2012) Imaging of beta-amyloid metal binding in yeast with x-ray fluorescence microscopy. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 8: 657-658.

Svendal G, Berk M, Pasco JA, Jacka FN, Lund A, Williams LJ (2012) The use of hormonal contraceptive agents and mood disorders in women. Journal of Affective Disorders, 140: 92-96.

Tang B, Dean B, Thomas EA (2012) Differential age- and disease-related effects of the expression of genes related to the arachidonic acid signaling pathway in schizophrenia, Psychiatry Research, 196: 201-206.

Toye C, Robinson A L, Jiwa M, Andrews S, McInerney F, Horner B, Holloway K, and Stratton B. Developing and testing a strategy to enhance a palliative approach and care continuity for people who have dementia: study overview and protocol. BMC palliative care 11: 4.

Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT Ikonomovic et al (2012) A-[beta] imaging: feasible, pertinent and vital to progress in Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging, 39: 209-219.

Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li QX, Masters CL, Pike KE, Rowe CC, Szoeke C, Taddei K, Villemagne VL, Martins RN; for the AIBL Research Group (2012) Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease. Molecular Psychiatry 23. doi: 10.1038/mp.2012.147.

Villain N, Chetelat G, Grassiot B, P Bourgeat, G Jones, KA Ellis, D Ames, RN Martins, F Eustache, O Salvado, Masters CL, Rowe CC, Villemagne VL (2012) Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB-PET longitudinal study. Brain. 135: 2126-2139.

Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chetelat G, O’Keefe G, Jones G, Kung HF, Pontecorvo M, Masters CL, Skovronsky DM, Rowe CC (2012) Differential Diagnosis in Alzheimer’s Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging. Neurodegenerative Diseases 10: 161-165.

Villemagne VL, Rowe CC (2012) Long Night’s Journey into the Day: Amyloid-β Imaging in Alzheimer’s Disease. Journal of Alzheimers Disease 33: S349-359.

Williams LJ, Pasco JA, Jacka FN, Dodd S, Berk M (2012) Pain and the relationship with mood and anxiety disorders and psychological symptoms. Journal of Psychosomatic Research, 72: 452-456.




Badcock P B, Moore E, Williamson E, Berk M, Williams L J, Bjerkeset O, Nordahl H M, Patton G C, and Olsson C A (2011) Modeling gene‐environment interaction in longitudinal data: Risk for neuroticism due to interaction between maternal care and the Dopamine 4 Receptor gene (DRD4). Australian journal of psychology 63: 18-25.

Berk M, Johansson S, Wray NR, Williams L, Olsson C, Haavik J, Bjerkeset O (2011) Glutamate cysteine ligase (GCL) and self reported depression: an association study from the HUNT. Journal of Affective Disorders, 131: 207-213.

Berk M, Malhi GS (2011) Should antipsychotics take pole position in mania treatment? Lancet, 378: 1279-1281.

Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi G S, Berk L, Conus P, and McGorry P D. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar disorders, 13: 87-98.

Caine JM,  Bharadwaj PR, SankovichSE, Ciccotosto GD, Streltsov VA, Varghese JN (2011) Oligomerization and toxicity of Aβ fusion proteins. Biochemical and Biophysical Research Communications, 409 (3), 477-482.

Conn CE, Mulet X, Moghaddam M, Darmanin C, Waddington LJ, Sagnella SM, Kirby N, Varghese JN, Drummond CJ (2011) Enhanced uptake of an integral membrane protein, the dopamine D2L receptor, by cubic nanoparticles doped with Ni chelated EDTA amphiphiles. Soft Matter, 7: 567-578.

Dilanian RA, Darmanin C, Varghese JN, Wilkins SW, Oka T, Yagi N, Quiney HM, Nugent KA (2011) Structural analysis of two-dimensional membrane protein crystals using x-ray powder diffraction data. Protein Science, 20: 457-464.

Gupta V, Wilson A, Rainey-Smith S, Laws S, Bush A, Ellis K, Macaulay L, Rowe C, Szoeke C, Taddei K, Ames D, Masters C, Martins R et al (2011) Establishing apolipoprotein E as a biomarker for Alzheimer’s disease: Australian Imaging, Biomarker and Lifestyle (AIBL) flagship study of ageing. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 8: 110-111.

Hung LW, Villemagne VL, Cheng L et al (2012) The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor cognitive functions in multiple animal models of Parkinson’s disease. Journal of Experimental Medicine, accepted.

Jacka, F. N., Pasco, J. A., Mykletun, A., Williams, L. J., Nicholson, G. C., Kotowicz, M. A., & Berk, M. (2011). Diet quality in bipolar disorder in a population-based sample of women. Journal of affective disorders, 129(1), 332-337.

Laws S, Lam CP, Mondal A, Bush A, Ellis K, Macaulay L, Rowe C, Taddei K, Szoeke C, Ames D, Masters C, Martins R (2011) Gene combination associations with Alzheimer’s disease risk and quantitative traits in the AIBL study. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 8: 678-679.

Laws S, Bender S, Rainey-Smith S, Wilson A, Gupta V, de Ruyck K, Bush A et al (2011) Alzheimer’s Disease – related changes in plasma cortisol levels and gene involvement in the AIBL study. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 8: 407.

Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M (2011) N-acetylcysteine for major depressive episodes in bipolar disorder. Revista Brasileira de Psiquiatria, 33: 374-378.

Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, and Berk M (2011) N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. Journal of affective disorders 129:317-320.

Rainey-Smith S, Brown B, de Ruyck K, Laws S, Wilson A, Gupta V, Ames D, Ellis K, Taddei K, Head R, Macaulay L, Masters C, Rowe C, Szoeke C, Martins R et al (2011) Alzheimer’s disease related changes in plasma brain-derived neurotropic factor levels. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 8: 407-408.

Williams LJ, Brennan SL, Henry MJ, Berk M, Jacka FN, Nicholson GC, Kotowicz MA, Pasco JA (2011) Area-based socioeconomic status and mood disorders: cross-sectional evidence from a cohort of randomly selected adult women. Maturitas, 69: 173-178.

Williams LJ, Pasco JA, Jacka FN, Henry MJ, Dodd S, Nicholson GC, Kotowicz MA, Berk M (2011) Bipolar disorder and adiposity: a study using whole body dual energy X-ray absorptiometry scans. Acta Neuropsychiatrica, 23: 219-223.